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The Mixed Lineage Leukemia (MLL) is a Trithorax (Trx) transcriptional regulator often 
implicated in leukemic oncogenesis. MLL1 rearrangement leukemia is a very aggressive form of 
leukemia that results from a translocation of chromosome 11q23. The translocation gives rise to 
a chimeric protein that consists of the N-terminus MLL and 1 of more than 80 fusion partners. 
The most common fusion partners are ENL, AF9, and AF4. ENL and AF9 are a part of the 
YEATS family of proteins, containing an N-terminal histone acetylation reading YEATS domain 
and a C-terminal ANC1 homology domain (AHD). AF9 and ENL’s AHD recruit either the Super 
Elongation Complex (SEC) or the histone 3 lysine 79 (H3K79) histone methyltransferase (HMT) 
disrupter of telomeric silencing 1-like (DOT1L) to activate gene transcription. Recruitment of 
DOT1L proved to be essential for the transforming activity of multiple MLL fusion proteins. Our 
lab mapped the 10 amino acid (865 – 874) binding site on DOT1L, which binds to the AHD 
domain of AF9/ENL. Applying alanine mutagenesis studies, a point mutation, I867A, was 
identified sufficient to disrupt the AF9-DOT1L interaction in vitro and demonstrated that 
DOT1L lacking the 10 amino acids (Δ10) was unable to support transformation by MLL-AF9. In 
this study, we used a genetic approach to explore the role of DOT1L recruitment in 
leukemogenesis and normal hematopoiesis to further validate the disruption of the AF9-DOT1L 
and ENL-DOT1L protein-protein interactions (PPI) as a potential therapeutic approach. We 
demonstrate that disrupting the AF9-DOT1L PPI inhibits leukemic cell growth, downregulates 
HOXA9 and MEIS1 gene expression, leading to cell differentiation and inducing apoptosis. 
These observed effects were similar to enzymatic inhibition. Nevertheless, PPI deficient adult 
   
 
xvii 
hematopoietic cells completely reconstituted the bone marrow of mice; whereas, cells lacking 
DOT1L or its catalytic activity were not. We successfully designed a DOT1L peptidomimetic 
with a KD of 10 nM against AF9 and 25 nM to ENL that is cellularly active and selective for 
MLL-AF9 transduced murine cells over a non-DOT1L dependent, E2A-HLF, cells. These results 
emphasize the critical role of the AF9-DOT1L PPI in leukemic cell growth, but not for adult 
hematopoiesis making it an attractive therapeutic approach for MLL-rearrangement leukemia. 
Due to the homology between the AHD domain of AF9 and ENL, we utilized the same 
genetic approach as with MLL-AF9 to determine if blocking DOT1L recruitment in MLL-ENL 
cells would yield the same effect on leukemogenesis. We showed that blocking DOT1L 
recruitment is not sufficient to fully inhibit leukemic cell growth. We postulate that this is due 
the retention of the YEATS domain in the MLL-ENL fusion that is lost in MLL-AF9. We 
characterized two interactions that could be contributing to leukemogenesis, Paf1-YEATS, and 
YEATS-H3. We demonstrate that Paf1 directly interacts with ENL YEATS with a binding 
affinity of 15 nM and confirm the YEATS-H3K27ac interaction with a binding affinity of 80 
M. We developed a fragment-based screening method using DSF to identify compounds that 
bind to the YEATS domain. The development of these tools will allow us to probe both the 
YEATS-Paf1 and YEATS-H3 interactions to determine which interactions are critical for MLL-
ENL driven leukemia. Overall, these studies show the characterization of several PPIs involved 
in MLL-AF9/ENL leukemia and the development of tools to further elucidate their roles in 





1.1 Epigenetics  
Each cell is comprised of the same genetic material, DNA; however, cell and tissue-
specific transcription and DNA damage repair are regulated by epigenetic signatures that drive 
cell fate based on which genes are accessible by transcriptional machinery.
1-3
 Epigenetic 
signatures affect genes through heritable phenotypic changes that do not involve altering the 
DNA sequence through the addition of functional groups to specific locations on DNA that can 
regulate transcription.
4,5
 These alterations or post-translational modifications (PTMs) consist of 
DNA methylation, small-noncoding RNAs and histone modifications(Figure 1-1).
6-8
 The 
presence or absence of PTMs modulates the formation of euchromatin (open chromatin) or 
heterochromatin (closed chromatin). 
9
 The accessibility of chromatin directly impacts the ability 
of transcription factor localization and RNA polymerase II recruitment to specific genes in 
response to developmental and environmental cues which is essential for healthy development 
and homeostasis.
10-14
 This dissertation work focuses on the epigenetic regulation of histones in 
leukemic and non-leukemic development.  
2 
 
Histone modifications are covalent PTMs to histone proteins 
like methylation, phosphorylation, acetylation, ubiquitylation, sumoylation, and others.
15,16
 
PTMs are deposited by writer enzymes, removed by eraser enzymes and recognized by reader 
proteins.
17
 The combination of reader, writer, and eraser proteins control the epigenome and 
chromatin structure regulating gene transcription.
15
 
Figure 1-1 Overview of epigenetic histone regulation and common histone regulating 
proteins.  
 
1.1.1 Epigenetic writers, erasers, and readers 
1.1.1.1 Epigenetic writers 
Histone acetyltransferases (HATs) and Histone methyltransferases (HMTs) are histone 
modifying enzymes that regulate gene transcription.
18,19
 Histone acetylation was proposed to 
affect DNA transcription in the 1960s.
20
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their initial discovery, 5 subfamilies of HATs emerged including GNATs (Gen5-
acetyltranferases), MYSTs, SRC (steroid receptor coactivators), p300/CBP HATs and general 
transcription factor HATs that contain the TAFII250 (Tetrahymena thermophila II) domain.
18,21-24
 
HATs acetylate lysine residues of histones by transferring an acetyl group from its cofactor 
acetyl-CoA.
25
 To date, the presence of an acetyl-lysine is generally linked to gene activation and 
euchromatin.
26,27
 HATs have also been shown to acetylate non-histone proteins like nuclear 
receptors and other transcription factors.
28-30
 
HMTs are subdivided into SET domain-containing proteins, non-SET domain-containing 
proteins, and arginine-specific proteins that use s-adenosylmethionine (SAM) as a cofactor to 
catalyze the transfer of a methyl group to the lysine or arginine residue of histones.
31-33
 SET 
domain containing HMTs like SuVar39, Enhancer of Zeste, and Trithorax can to methylate both 
histones 3 and 4 (H3 and H4).
33,34
 Whereas, a non-SET domain containing HMT, Disruptor of 
telomeric silencing 1-like (DOT1L), is only able to methylate H3 due to the structural constraints 
of its SAM-binding site.
35
 HMTs can either mono-, di-, or tri- methylate the amino group of 
lysine residues.
36
 These HMTs regulate transcription methylation by either activating or 
repressing transcription depending on the context and level of methylation.
37
 Modifications 
associated with gene activation include di- and tri H3K4 (H3K4me2 and H3K4me3), mono-, di-, 
and tri-H3K79 (H3K79me1 HeK79me2 and H3K79me3). Conversely, di- and tri-methylation of 
H3K9 and H3K27 (H3K9me2, H3K9me3, H3K27me2, and H3K27me3) are repressive marks.
38
  
Protein arginine methyltransferases (PRMTs) are a subset of HMTs that specifically 
mono- or di- methylate arginine residues on histone tails. Arginine methylation marks are 
associated with gene activation (H4R3me2, H3R2me2, H3R17me2, H3R26me2) or repression 
(H3R2me2, H3R8me2, H3R8me2, H4R3me2).
39
 Recently, newer modifications, like lysine 
4 
 
crotonylation (Cr) have added to the complexity of histone gene regulation.
40
 The “epigenetic 
code” is a combination of histone PTMs like Me, P, Ac, Ub, and Cr that are involved in creating 
binding surfaces for protein complexes that are involved in chromatin and transcriptional 
regulation. 
1.1.1.2 Epigenetic erasers 
 Epigenetic erasers are comprised of four classes of enzymes, histone deubiquitinases, 
histone phosphatases, histone deacetylases, and histone demethylases that can remove histone 
ubiquitination, phosphorylation, acetylation, and methylation PTMs respectively.
41-44
 Histone 
deacetylases (HDACs) and histone demethylases. HDACs are enzymes capable of removing 
acetylation marks from histones and silence transcription. There are four classes of HDACs.
41
 
Class I comprised of HDACS 1, 2, 3, and 8. Class IIa comprised of HDACs 5, 7, and 9. Class IIb 
comprised of HDACs 6 and 10. Class III is comprised of all of the sirtuins (SirT1-7) while class 
IV contains only HDAC11.
45,46
 Class I HDACs are known to be ubiquitously expressed and 
traditionally localize in the nucleolus.
47
 It is thought that this class of HDACs predominantly 
deacetylate histone substrates repressing gene transcription.
48
 Class I HDACs are highly 
conserved enzymes consisting or mainly the deacetylase domain with minimal amino acid 
extensions at the N- and C-terminus of the domain.
49
 Knockout (KO) studies of the different 
Class I HDACs demonstrated that even though the enzymes are similar in structure, they are 
required for different functions in development. HDAC1 and 3 KO in mice is embryonic lethal 
with defects in proliferation and gastrulation respectively.
49-51
 In contrast, HDAC2 and 8 KO 
mice produce viable offspring; however, they do not survive longer than 1 day postnatal.
50,52
 
HDAC2 KO mice develop cardiac malformation
50
 while HDAC8 KO mice were observed to 
have craniofacial defects.
53
 Class IIa HDACs have a large N-terminal extension that consists of a 
5 
 
myocyte enhancer factor 2 (MEF2) binding domain, chaperone protein 14-3-3 binding site 
before the deacetylase domain. Upon phosphorylation, class IIa HDACs bind to the chaperone 
14-3-3 proteins, shuttling it from the nucleus into the cytoplasm. Once this class of HDAC is in 
the cytoplasm, it no longer binds MEF2, leaving it to associate to HAT p300 converting MEF2 
from a gene repressor to a gene activator.
54,55
 Unlike class I HDACs, class IIa HDACs have more 
tissue-specific expression patterns. HDAC4 is highly expressed in the brain and skeleton.
54,56
 
HDAC5 and 9 are highly expressed in the muscles, heart, and brain.
57,58
 HDAC7 is expressed in 
thymocytes and endothelial cells.
59
 Class IIb HDACs share homology in their deacetylase 
domains but have very different structures. HDAC6 and 10 are the main cytoplasmic 
demethylase and is the only HDACs with 2 demethylase domains.
41,60
 HDAC6 deacetylates 
transmembrane proteins, chaperones, and cytoskeletal proteins.
61-64
 Whereas, HDAC10 was 
recently shown to have immunoregulatory activity.
65
 Class III HDACs, the Sirtuins, have a 
complexity of functions in various locations of the cell. They can deacetylate a variety of histone 
and non-histone substrates, and in addition to deacetylating substrates, SIRT5 can also 
desuccinylate and demalonylate proteins. Each sirtuin resides in different compartments in the 
cell. SIRT1 and SIRT2 are nuclear and cytoplasmic, SIRT3 is nuclear and mitochondrial, SIRT 4 
and 5 are only mitochondrial, SITRT6 and 7 are found in the nucleus. Last, is the class IV 
HDAC11, which is the only HDAC in the class.
66
 HDAC11 regulates the stability of DNA 
replication factor CDT1 and the expression on IL-10.
67
 It is highly expressed in the brain, heart, 
muscle, kidney, and testis.
66,68
 The interplay between lysine acetylation and deacetylation 
regulates not only histones and transcription but other HATs and HDACs, in various cellular 





 Like HDACs, histone demethylases modulate the various methylation marks to either 
repress active genes by demethylating activating marks or removing repressive marks to leave a 
gene poised for activation. Histone demethylases are clustered into two classes: amino oxidase 
homolog lysine demethylase 1 (KDM1) and JmjC domain-containing histone demethylases. 
KDM1 family of enzymes were first discovered because of their ability to demethylate the 
mono- and di-methylation states of lysine 4 on histone 3; however, due to the flavin adenine 
dinucleotide (FAD)-dependent amine oxidase reaction, tri-methylation cannot be demethylated 
by this enzyme.
70
 This substrate limitation is overcome by the JmjC domain-containing 
demethylase that no longer require protonation of the lysine group and instead uses a 
hydroxylation reaction.
71-75
 Together, both KDM1 and JmjC families of demethylases help 
maintain the balance of gene transcription of various cellular contexts. To date, all histone 
methylation marks have demethylase that can remove it excluding H3K79me. DOT1L is the only 
known histone methyltransferase to deposit H3K79me that was thought to only be removed 
during histone turnover.
76,77
 Recent reports identified KDM2B as the first H3K79 demethylase.
78
  
1.1.1.3 Epigenetic readers 
 Equally as important as writing and erasing histone modifications is for creating the 
messages through PTMs that regulate gene expression, gene locus specificity is needed to ensure 
the proper genes are activated and repressed. This specificity is achieved through epigenetic 
reader motifs that target histone modifying enzymes and complexes to the proper gene locus.
79
 
This specificity is mediated by protein-protein interaction (PPI) networks. These networks use 
readers to recognize the presence or absence of histone modifications and recruit other histone 
modifying enzymes or polymerase stabilizing complexes to regulate gene expression. In the case 
of histone acetylation, bromodomains and PHD finger are the two most common domains 
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associated with reading acetyl-lysine residues that bind to acetylated histones with a relatively 
weak binding affinity.
80-82
 There substantial redundancy and overlap across the HATs in their 
gene activating capabilities. It is thought that acetylation marks work in tandem which allows for 
differential binding of readers to gene loci based on the number of histone reader domains 
present on the protein. The interplay of reader domain number and number of acetylation marks 
present at a gene locus helps to facilitate specific transcription.
83,84
  
Interestingly, PHD domains ecognize not only acetylation marks but also unmodified 
H3K4 and histone methylation showing the diversity of functions among common readers.
85
 
Histone methylation is one of the most stable histone marks. Several methylation readers in 
conjunction with PHD, recognize both unmethylated H3K4 and modified histone residues 
including WD40 and ADD domains.
86
 Other histone lysine readers like the Chromo, Tudor, 
MBT, PWWP and other domains read methylated histones.
87
 Interestingly, outside of the 
canonical reader domains, Bromo-adjacent homology (BAH) domain on Sir3 is the only 
H3K79me reader reported to date.
88,89
 Unlike histone acetylation readers, methylation readers 
bind more tightly to their designated marks.  
1.1.1.4 Novel histone acylations and the novel acyl lysine reader YEATS domain 
In recent years, due to the emerging role of histone acylation in cellular metabolism, there 
has been a push towards identifying novel histone acylation marks in addition to histone lysine 
acetylation.
40,90
 Using new proteomic techniques, new acylations like crotonylation (Kcr), 2-
hydroxyisobutyrylation (Khib), beta-hydroxybutyrylation (Kbhb), succinylation (Ksu), and many 
others were identified.
40,91-94
 Most of the newly identified acyl modifications have the same 
pattern of histone acylation as lysine acetylation (Kac).
40
 Interestingly, Kcr and Khib have 
additional acylation sites suggesting non-acetyl functions. The presence of these new acylation 
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groups has been implicated in spermatogenesis, inflammation, and starvation.
40,93,95
 Histone 
acetyltransferase, p300, was identified as a HAT capable of transferring larger acyl groups from 
the respective acyl-coenzyme A (acyl-CoA) donor molecules and intermediate metabolites.
95-98
 
In addition to identifying histone acyl writers, HDAC3, Sirt1, Sirt2, and Sirt3 were identified as 




 In the midst of discovering these emerging acyl lysine marks, the YEATS domain, a new 
histone lysine acylation reader, was discovered that specifically recognizes histone lysine 
acylation marks preferring crotonylation over all other acylations with acetylation as the 
weakest.
101,102
 The YEATS domain is structurally unique from other acyl lysine readers in that is 
adopts an aromatic sandwich pocket that envelops the long chained crotonyl group leaving an 
open-ended whole so that there is no steric hindrance with the protein making it ideal for loner 
groups.
103
 This interaction is stabilized by an aromatic--aromatic stacking around the Kcr 
group.
104
 In contrast, the bromodomain binding pocket has a shallower binding groove with an 
opening at the side, making it more suitable for shorter acylations.
103
 Out of the bromodomain-
containing proteins, only the second bromodomain of TAF1 and BRD9 can accommodate Kcr.
105
 
Recently, proteins containing double PHD finger (DPF) domains were characterized as another 
class of Kcr readers that has a different mechanism of Kcr recognition from the YEATS domain, 
incorporating complete encapsulation of the mark and hydrogen bonding.
106
  
The YEATS family of proteins was first identified in yeast and is conserved through 
humans.
107
 In humans, GAS41, YEATS2, ENL, and AF9, are only YEATS domain-containing 
proteins to date.
101-103,107-110
 GAS41 is known to recruit the HAT, Tip60, to facilitate histone 
acetylation or enable H2A.Z deposition through SRCAP.
111
 YEATS2, recruits HATs to 
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chromatin to facilitate acetylation.
107
 AF9 and ENL are the most structurally similar human 
YEATS family members containing an N-terminal YEATS domain and C-terminal AHD domain 
that is important for mediating PPIs with other histone modifying proteins that are involved in 
transcription elongation, chromatin remodeling, and histone methylation.
107-109
  
1.1.2 Histone crosstalk for regulation of gene activation  
 As aforementioned, PTM of various residues on histones can either positively or 
negatively impact transcription. Combinations of various histone PTMs and the recruitment of 
the associated protein complexes by the modifications lead to the physical modification of 
chromatin structure yielding a specific transcriptional outcome.
112,113
 Histone crosstalk is a term 
to describe the complexity of histone modifications coregulation of adjacent marks dynamically 
to regulate transcription.
114
 For example, H3K4me3 is enhanced by monoubiquitination of H2B; 
however, H3K4 methylation can be inhibited if the adjacent H3R2 is methylated first.
114
 The 
many dynamic and critical roles of epigenetic regulators in development and homeostasis point 
to many areas where dysregulation of these signatures can lead to various human diseases such 
as cancer. 
1.2 MLL family of proteins 
Six proteins comprise the MLL family of histone methyltransferases, SETD1a, SETD1b, 
MLL1, MLL2, MLL3 and MLL4 (Figure 1-2A). MLLs function in multi-protein complexes that 
regulate their function to mono-, di- or tri- methylate H3K4.
115
 MLL family of proteins cluster 
into 3 subfamilies similar to their Drosophila counterparts. SETD1a and SETD1b cluster into 
Set1-like proteins, MLL1 and MLL2 cluster into TRX-like proteins and MLL3 and MLL 4 are 
most similar to TRR-like proteins (Figure 1-2B). SETD1a and SETD1b are noted to regulate 





 MLL1-4 regulate developmental genes.
118
 MLL1 and MLL2 target Hox and other 
genes by depositing H3K4me2 or H3K4me3 at the promoter regions or Polycomb response 
elements (PRE).
119-121
 In contrast, MLL3 and MLL4 function by monomethylating 
enhancers.
121,122
 All six MLLs are part of protein complexes that are necessary for their 
function.
119
 Each complex contains proteins ASH2, RBBP5, WDR5, and DPY30.
123-125
 The 
addition of WDR82 and CXXC1 are critical for the function of SETD1a and SETD1b.
126,127
 
While, MLL1 and MLL2 both use the protein menin to help the complex interact with DNA. 
127-
129
 MLL3 and MLL4 harboring complexes are distinguished by the presence of UTX, PXIP1, 




Figure 1-2 The MLL family of histone methyltransferase.  
(A)Schematic of the important domains and cleavage points in each of the MLL family of H3K4 
methyltransferases. (B) Phylogenetic tree showing the clustering of MLL family members by 
their Drosophila counterparts TRX-like (MLL1 and MLL2), TRR-like (MLL3 and MLL4), and 






























1.2.1 MLL1 and MLL2 in embryogenesis and development 
 MLL1 and MLL2 are closely related proteins that are required for embryogenesis; 
however, have distinct roles in development. Mll
-\-
 mice are embryonic lethal at E10.5 with a loss 
of posterior Hox gene expression. Mll 
+/-
 mice; however, can develop through adulthood, but they 
exhibit stunted growth, altered hematopoiesis, and an altered skeletal system.
136
 These findings 
are similar to the structural abnormalities seen in Drosophila trx mutants.
137
 A study showed that 
Mll1 had a selective reduction of H3K4 in only about 5% of genes including not only Hox genes 




 mice also die at E10.5; however, a 
conditional knockout at E8.5 yields a normal mouse with no noticeable defects other than in 
reproductive development.
138,139
 This finding points to a distinctive difference in developmental 
regulation between the hematopoietic and skeletal development specific involvement of MLL1 
and the reproductive targeted MLL2. 
1.2.2 MLL1 and leukemogenesis 
 Mll1 gene is located on 11q23 chromosome that encodes a 3696 amino acid (aa) protein 
that is comprised of two subunits, an N-terminal subunit, and a C-terminal subunit.
140
 MLL1 is 
proteolytically cleaved by threonine aspartase 1 (TASP 1), an endopeptidase that cleaves 
proteins into substrates by cleaving after an aspartate residue (Figure 1-2A).
141,142 
After cleavage, 
C-terminus and N-terminus fragments associate with each other by the consensus interaction 
motifs. The N-terminus of MLL1 does not contain any histone modifying domains; however, the 
C-terminus contains a SET domain that carries out the H3K4 methylation. Both N- and C-
terminal regions of DOT1L recruit various histone binding and modifying proteins to facilitate 
its overall function. Hallmarks of this protein are the CxxC domain that shares homology with 
other histone methyltransferases; four plant homeodomain (PHD) fingers, a transactivation 
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domain, and a SET domain. MLL1 chromatin binding is mediated by the N-terminus of MLL1 
and its interactions with multiple endocrine neoplasia 1 (MEN1) and lens epithelium-derived 
growth factor (LEDGF).
128,129,143,144 
These PPIs are important for the recruitment of MLL1 to 
chromatin.
145,146 
The N-terminus of MLL1 also recruits polymerase-associated factor (PafC) via 
the CxxC motif that is located nears the MLL1 protein cleavage point. PafC then recruits super 
elongation complex (Sec) and positive transcription elongation factor (pTEFb). Along with 
histone methylation capabilities, C-terminal MLL1 can recruit MOF, a histone 4 lysine 16 
(H4K16) acetyltransferase.
147
 Other recruited proteins on the C-terminus of MLL1 are CREB-
binding protein (CBP), WD repeat domain 5 (WDR5) and others.
115
 Recruitment of the other 
proteins named above and association of both termini of MLL allow for its function to remodel 
chromatin and carry out its enzymatic activity.
115
  
 Chromosomal translocations of the Mll1 gene result in fusion of the N-terminus of the 
protein to one of greater than 80 fusion partners.
148
 Out of the many MLL-fusion proteins that 
have been identified there are six common partners (AF4, AF9, ENL, AF10, ELL, and AF6) that 
make up the majority of MLL-fusion leukemia.
148 
MLL fusion partners AF9, ENL, AF4, and 
AF10, make up 93% and 49% of all MLL-driven acute lymphoblastic and acute myeloid 
leukemias, respectively.
149
 The translocation event removes MLL1’s ability to modify histones 
due to the loss of the C-terminal SET domain and recruit MOF to acetylate histones.
150,151
 
However, the fusion partner can recruit new protein complexes like the Super Elongation 
Complex (SEC) and DOT1L Complex (Dotcom).
152,153
 The presence of the MLL-fusion proteins 
leads to the misregulation of MLL1 target genes like HOXA9 and Meis1 leading towards 
leukemogenesis by mistargeting gene-activating protein complexes.
154
 MLL rearranged leukemia 
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is a type of aggressive blood cancer found in more than 70% of infant leukemias, more than 10% 
of therapy-resistant acute myeloid leukemia (AML) and 5% of de novo AML cases.
155
 
1.3 Common MLL fusion proteins and complexes in leukemogenesis  
1.3.1 Super Elongation Complex 
 MLL-ELL was one of the first identified MLL1 fusion partners.
156
 ELL suppresses 
pausing of RNA Pol II, which links its presence with stabilizing active transcription.
157
 Along 
these lines, other MLL1 fusion partners, AF4, AF9, and ENL, are all associated with the SEC 
complex.
158
 AF4 acts as a scaffolding protein and interacts with multiple subunits of SEC. 
Directly AF4 binds to ELL and positive transcription elongation factor (p-TEFb) to 
phosphorylate the C-terminal domain of RNA Pol II that releases it from promoter-proximal 
pausing (Figure 1-3A).
159
 Knockdown of any of the SEC subunits in cells harboring one of these 
MLL-fusions in the SEC complex, leads to a decrease in leukemogenesis.
160
 Overall, this 
mechanism shows that an MLL-fusion protein harboring any of the SEC subunits can act as a 
scaffolding site for the recruitment of the remaining SEC proteins, stabilizing RNA Pol II 
leading towards the aberrant transcription of HOX genes and leukemic progression.
152
 
1.3.2 DotCom Complex 
 Along with the SEC complex, the Dot1 complex (DotCom) is also recruited by native 
binders of DOT1L that are translocated to MLL1.
161
 The proteins involved in DotCom are AF9, 
ENL, AF10, and AF17 (Figure 1-3B). MLL-AF9 and MLL-ENL fusions are able to directly 
recruit both the SEC and DotCom complexes to MLL1 target genes in a mutually exclusive 
manner either through AF4 of the SEC complex or DOT1L of DotCom (Figure 1-3C).
162
 
Whereas, MLL-AF10 and MLL-AF17 can directly recruit DotCom through DOT1L interactions 
or indirectly recruit SEC.
162,163
 In addition to the recruitment of DOT1L directly by fusion 
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proteins, other groups have noted the ability of DOT1L to associate with p-TEFb, AF4 and other 
components of the SEC complex.
152
 DOT1L has also been shown to interact with Wnt factors 
like TRRAP, SKP1, and Beta-catenin.
161,164
 Inhibiting DOT1L’s catalytic activity or removing 
Dot1l in mice with MLL-rearrangement leukemia inhibits leukemogenesis. Some groups have 
attributed this to Wnt signaling and Beta- catenin’s role in leukemogenesis.
165
 However, DOT1L 
driven leukemogenesis in MLL-AF9 and MLL-ENL leukemia is primarily attributed to 
DOT1L’s recruitment to MLL-target gene loci.
166-168
 The role of DOT1L and distinct mechanism 
in various fusion protein settings is still being elucidated; however, significant work has been 
done validating it as a therapeutic target for MLL-fusion leukemia.  
 
Figure 1-3 Common MLL-fusion protein complexes in MLL-rearrangement leuekmia.  
(A) (Top) Schematic of the Super Elongation Complex (SEC) in complex with MLL-AF9 or 
MLL-ENL binding to AF4 recruiting the other subunits of SEC to MLL-target genes. (Bottom) 
Schematic of the different MLL-fusion proteins that recruit the DotCom complex to MLL-target 
genes depositing the H3K79 methylation mark and driving gene expression. (B) Solution NMR 
structure of the AF4-AF9 (yellow) and AF9-DOT1L (red) interaction overlaid to show the 







1.4 Disrupter of Telomeric Silencing 1-like (Dot1l) 
The disruptor of telomeric silencing 1 (Dot1) gene was identified in a yeast genetic 
screen in which overexpression of the gene reduced silencing at telomeres and other repressed 
genes.
170
 The function of Dot1 is conserved from yeast to humans; thus, the human homolog 
DOT1L has the same histone methyltransferase enzymatic activity. DOT1L is a non-SET 
domain-containing histone methyltransferase solely responsible for mono-, di-, and tri-
methylation of H3K79. Knock out of Dot1l leads to a ubiquitous loss of H3K79 methylation 
suggesting there is no other enzyme to date responsible for this methylation mark. Also, there is 
no known demethylase of H3K79 methylation. DOT1L exclusively methylates on histones cores 
and is unable to methylate free histone tails.  
1.4.1 Wildtype DOT1L regulatory functions 
H3K79 methylation has numerous implications in development and normal biological 
processes. Dot1l null mice die between 9.5-13.5 days postcoitum.
171,172
 Defects in yolk sac 
angiogenesis and cardiac dilation are suspected as the major cause for embryonic lethality. 
Embryonic stem cells derived from Dot1l mutant blastocysts display deficient heterochromatin 
establishment at centromeres and telomeres due to aneuploidy, telomere elongation, and 
proliferation defects.
173
 Furthermore, defects in erythropoiesis were observed with deficient 
erythroid development, G0/G1 accumulation, and increased apoptosis, demonstrating an 
important role for Dot1l in prenatal hematopoiesis.
174
  
Conserved from yeast to higher eukaryotic organisms, Dot1l is involved in double-strand 
break repair.
175
 Loss of Dot1l results in defects in cell cycle regulation. In murine bonemarrow 
derived cell line, conditional loss of Dot1l leads to cell cycle arrest at G1/S phase and 
accumulation of G0/G1 cells with loss of S and G2/M phase cells.
175
 In embryonic stem cells, 
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Dot1l loss blocks cell differentiation as a result of cell cycle arrest in G2/M phase and 
proliferation arrest. These studies indicate that Dot1l is required for the regulation of gene 
transcription in the early stages of embryonic stem cell differentiation.
175
 Dot1l is also involved 
in mediating sodium (Na
+
) uptake in epithelial cells in response to aldosterone via regulation of 
the epithelial Na
+
 channel (ENaC) gene via H3K79 methylation of the gene promoter.
175
 The 
mutually exclusive binding of either AF9 or AF17 mediates DOT1L’s activity at the ENaC gene 
locus.
175
 Additionally, DOT1L has a role in cardiac function by regulating the expression of the 
Dystrophin (Dmd) gene required for stabilization of the dystrophin-glycoprotein complex 
important for cardiomyocyte viability. Cardiac-specific loss of DOT1L results in cardiomyocyte 
cell death, heart chamber dilation, and systolic dysfunction phenotypes.
176
 DOT1L methylation 




Due to embryonic lethality and the need to understand the biological function of DOT1L 
in mammals, especially its role in MLL-fusion protein-mediated leukemogenesis, several 
conditional Dot1l deletion models were generated.
176
 Conditional knockout of Dot1l in a 
postnatal setting demonstrated that systemic loss of Dot1l did not produce toxicity for 7-8 weeks. 
Mice with floxed Dot1l at 6-10-week-old were injected with tamoxifen to induce CreER 
mediated excision of Dot1l and showed complete loss of H3K79 methylation in bone marrow 
cells and other tissue. Mice lacking Dot1l became moribund and developed pancytopenia 8-12 
weeks after tamoxifen injection. These findings demonstrated that Dot1l is required to maintain 





1.4.2 DOT1L as a validated therapeutic target for MLL-rearrangement leukemia 
 Several preclinical reports note the importance of DOT1L in MLL-fusion 
leukemogenesis.
162,177
 This is demonstrated by the upregulation of H3K79 methylation at a 
subset of MLL target genes such as HoxA genes and Meis1 that are distinct from normal 
hematopoietic progenitor cells or other Acute Lymphoblastic Leukemias (ALLs) with germline 
MLL1. The aberrant H3K79 methylation profile in MLL-fusion ALLs also correlated with 
increased gene expression, especially for the HoxA gene cluster.
176
 
These reports demonstrate that MLL-fusion proteins recruit DOT1L to MLL1-target 
genes where it carries out its enzymatic function of H3K79 methylation. Aberrant methylation 
leads to increased expression of genes such as HoxA9 and Meis1 which are critical transcription 
factors driving leukemogenic transformation.
130
 Loss of DOT1L results in decreased H3K79 
methylation and reduced expression of MLL1-target genes inhibiting leukemogenic 
transformation.
178,179
 Several MLL-fusion proteins that have not been shown to interact with 
DOT1L directly also appear to depend on the histone methyltransferase for leukemogenic 
transformation although the mechanism is not understood.
180
 Based on this model, DOT1L is an 
attractive therapeutic target for the treatment of leukemias bearing translocations of MLL1.  
1.5 Therapeutic approaches for targeting DOT1L in leukemia 
1.5.1 Targeting DOT1L catalytic domain  
S-adenosylhomocysteine (SAH; Figure1-4), the demethylated reaction product of 
DOT1L enzymatic activity, was reported that can inhibit DOT1L enzymatic activity in 
nanomolar concentration. However, many enzymes utilize the SAM cofactor and are similarly 
inhibited by SAH, and significant efforts in academia and industry were aimed towards the 
development of selective DOT1L inhibitors. The first selective and cell active, SAM competitive 
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DOT1L inhibitor was EPZ004777 with Ki of ~0.3 nM and >1,000-fold selectivity for DOT1L 
over other HMTs.
57
 The complex structure of EPZ004777 with DOT1L, revealed a significant 
conformational change in the SAM-binding pocket upon binding of the inhibitor, contributing to 
its selectivity to DOT1L. Upon EPZ004777 binding, an adjacent hydrophobic pocket is opening 
due to the DOT1L confirmation changes, where the tert-butyl phenyl group binds and contributes 
to its high binding potency and selectivity. Subsequent modifications led to the development of 
clinical candidate EPZ-5676, Pinometostat. (Figure 1-4)  
In addition to Pinometostat, several covalent inhibitors of DOT1L were reported with 
subnanomolar potency.
181
 (Song-1; Figure1-4) It is well known that adenosine derivatives have a 
very short half-life; thus there has been much attention devoted to the synthesis of inhibitors with 
improved metabolic stability. The first non-adenosine SAM analog inhibitor, Song-2, was 
reported where the ribose was replaced with a bioisostere, a cyclopentane. The non-adenosine 
compound is 2-3-fold weaker than its adenosine counterpart but has improved metabolic stability 
in a liver microsome assay.
182
 (Song-2; Figure1-4) Recently, a new non-adenosine molecule was 
developed based on a fragment linkage approach fully abandoning the furan or cyclopentane 
core scaffold inherent to most SAM competitive molecules.
183
 (Gaul-1; Figure 1-4) Gaul-1 is the 




Figure 1-4 Potent inhibitors of DOT1L enzymatic activity.  
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1.5.2 Dot1l inactivation on non-leukemic hematopoiesis 
 Initially, it was demonstrated that DOT1L is required for embryonic development and 
DOT1L null mice die between 9.5-13.5 days postcoitum.
184,185
 DOT1L deficient mice suffered 
from anemia and defective erythroid differentiation. Considering the potential for targeting 
DOT1L in leukemia, there is significant interest to investigate the role of DOT1L in normal 
hematopoiesis in developed mice. Therefore, conditional knockout models of DOT1L were 
developed and demonstrated that DOT1L is essential for maintenance of normal adult 
hematopoiesis. The inducible knockout of Dot1l led to depletion of hematopoietic stem cells and 
various lineage progenitors (granulocyte, monocyte, megakaryocyte, erythrocyte, etc.). This 
resulted in severe anemia and overall decrease in the bone marrow cellularity.
186,187
 In contrast, a 
third study using DOT1L knockout in the hematopoietic compartment reported that mice display 
anemia with hypocellularity in the bone marrow, but DOT1L depletion did not cause a total loss 
of myeloid or lymphoid development.
177
 Additional studies which target the enzymatic activity 
of DOT1L using the small molecule inhibitor EPZ004777 demonstrate a decrease in committed 
progenitor cells that was most apparent in common myeloid progenitors and 




1.5.3 Targeting DOT1L’s recruitment by MLL-fusion proteins 
As mentioned previously, studies have shown that the PPIs between MLL-fusion proteins 
and DotCom/SEC are required for leukemogenesis.
152,160,168
  Two of the most common fusions 
are MLL-AF9 and MLL-ENL. Both AF9 and ENL belong to YEATS domain protein family 
containing an N-terminus YEATS domain and a C-terminal hydrophobic, ANC1 
homology domain (AHD), domain that binds to AF4 or DOT1L. NMR studies show that when 
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the C-terminus of AF9 is not bound to another protein, it is intrinsically disordered and becomes 
ordered upon ligand binding.
118
 This has been demonstrated by observing the NMR structure of 
AF9-AF4 PPI and AF9-DOT1L PPI (Figure 1-3B).
167,169
  For the first time, our group mapped 
the 10 amino acid interaction site between AF9/ENL and DOT1L (aa 865-874).
168
 This region of 
DOT1L shares sequence homology to AF4 consistent with previous reports of a mutually 
exclusive binding of AF9 to SEC and DotCom.
189,190
 Subsequent studies identified two 
additional sites; site 1 (aa 628-653), and site 3 (aa 878-900) that also interact with the AHD 
domain of AF9.
167
 Site 1 binds the weakest to AF9 whereas site 3 binds with similar potency to 
site 2 (aa 865-874) and share a similar sequence.
167
 Utilizing an alanine scanning approach, we 
were able to identify the residues isoleucine 867 and isoleucine 869 as critical hydrophobic 
anchors for DOT1L to bind to AHD.
168
 Additionally, when the entire 10 aa AF9 binding 
sequence on DOT1L is removed (10), MLL-AF9 transformed cells lost their self-renewal 
capabilities.
168




With the emerging evidence of the importance of DOT1L’s function in hematopoiesis, 
we set out to validate targeting the PPI between DOT1L/AF4 and MLL-fusion proteins such as 
MLL-AF9 and MLL-ENL. This approach offers the potential benefit of inhibiting DOT1L 
recruitment to MLL-target genes while allowing for normal H3K79 methylation regulation in 
hematopoietic stem cells and other cellular lineages. Therefore, we predicted that cells 
containing the MLL-AF9 and MLL-ENL fusion proteins would be selectively sensitive to 






The epigenetic landscape is vital for normal development and maintenance of tissue- and 
cell-specific functions.
10
 Misregulation of reader, writer, or eraser proteins can lead to various 
abnormal processes and cancer.
191,192
 Due to the apparent shift in epigenetic programming from 
normal to cancer states, many epigenetic regulators are being identified as potential therapeutic 
targets for drug intervention.
193
 In a variety of MLL-rearrangement leukemia subtypes, DOT1L’s 
catalytic domain was identified and validated as a therapeutic target.
183,188
 However, this 
approach does not take into account the functional importance of DOT1L in other tissues
175,176
 
and the potential on-target toxicities on non-leukemic hematopoiesis that may develop with the 
long-term, global enzymatic inhibition of DOT1L. Therefore, in order to leave DOT1L’s 
enzymatic activity intact, we set out to validate targeting DOT1L’s recruitment by MLL-AF9 
and MLL-ENL as an alternative therapeutic approach. By blocking DOT1L’s recruitment, it can 
carry out its normal functions in the absence of AF9 and ENL binding. To date, there is not 
enough evidence to determine if PPI inhibition will be more beneficial.  
To address the therapeutic advantage of targeting the AF9/ENL and DOT1L PPI over 
enzymatic inhibition of DOT1L, this dissertation work studied the importance of the AF9 
binding domain of DOT1L in leukemic cell growth by demonstrating that blocking the AF9 and 
DOT1L PPI inhibits cell proliferation, decreases H3K79me at MLL target genes HOXA9 and 
MEIS1, leading to a decrease in their expression, induction of cell differentiation and apoptosis. 
Furthermore, we clarified the importance of DOT1L enzymatic activity and not the AF9-DOT1L 
PPI for non-leukemic hematopoiesis (Chapter 2). In addition to genetically blocking DOT1L 
recruitment, we developed cell active and selective peptidomimetics that mimic DOT1L’s 
binding domain that interacts with the AF9/ENL AHD domain (Chapter 3). Based on previous 
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studies, we propose that the peptidomimetics can disrupt both AEP and SEC complexes in 
addition to blocking DotCom due to the conserved binding region on AF4 and DOT1L. These 
two studies highlight an alternative approach to targeting DOT1L that leaves its catalytic site 
intact to carry out its normal hematopoietic functions while specifically targeting the MLL-AF9 
transformed cells. Lastly, in Chapter 4, we aimed to understand the role of the MLL-ENL fusion 
protein’s YEATS domain on leukemogenesis. We confirmed that DOT1L alone is not solely 
responsible for leukemogenesis in MLL-ENL leukemia when the ENL YEATS domain is 
present. We also validated the direct interaction between Paf1 and ENL YEATS quantifying the 
binding affinity using a biophysical method and developed a fragment-based screening method 
to identify fragment molecules that bind the YEATS domain. These studies lay the foundation 
for developing chemical tools to interrogate the YEATS-PAF1 and YEATS-H3 interactions in 
leukemogenesis.  
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Elucidating the Importance of DOT1L’s AF9-Binding Domain in MLL-AF9 Leukemia and 
Normal Hematopoiesis 
2.1 Abstract 
MLL1 gene rearrangements underlie the pathogenesis of aggressive MLL-driven acute 
leukemias. AF9, one of the most common MLL-fusion partners, recruits the histone H3K79 
methyltransferase DOT1L to MLL-target genes, constitutively activating transcription of pro-
leukemic targets. DOT1L has emerged as a therapeutic target in patients with MLL-driven 
leukemia. However, global DOT1L enzymatic inhibition may lead to off-target toxicities in non-
leukemic contexts that could decrease the therapeutic index of DOT1L inhibitors. To bypass this 
problem, we developed a novel approach targeting specific protein-protein interactions (PPI) that 
mediate DOT1L recruitment to MLL fusion partners, and we compared the effects of enzymatic 
and PPI inhibition on leukemic and non-leukemic hematopoiesis. MLL-AF9 cell lines were 
engineered to carry mutant DOT1L constructs with a defective AF9 interaction site or lacking 
enzymatic activity. Utilizing the defective AF9 interaction mutant cell lines, we observed 
complete disruption of DOT1L recruitment blocking DOT1L recruitment to critical target genes 
and inhibiting leukemic growth followed by downregulation of H3H79 methylation leading 
towards a decrease in HOXA9 and MEIS1 expression, cell differentiation, and apoptosis. To 
evaluate the overall impact of DOT1L loss in non-leukemic hematopoiesis, we first assessed the 
impact of acute Dot1l inactivation in adult mouse bone marrow. We observed a rapid reduction 
in myeloid progenitor cell numbers within 7 days, followed by loss of long-term hematopoietic 
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stem cells. Furthermore, WT and PPI-deficient DOT1L mutants but not an enzymatically 
inactive DOT1L mutant were able to rescue long-term hematopoiesis. These data show that the 
AF9-DOT1L interaction is dispensable in non-leukemic hematopoiesis. Our findings support 
targeting of the MLL-AF9—DOT1L interaction as a promising therapeutic strategy that is 





2.2.1 Mixed Lineage Leukemia 
The Mixed Lineage Leukemia 1 (MLL1) gene is located on chromosome 11q23 and 
encodes a histone 3 lysine 4 (H3K4) methyltransferase.
1,2
 The MLL1 locus contains a breakpoint 
region upstream of the SET domain that is involved in chromosomal translocations, generating 
oncogenic fusion proteins that combine its DNA binding N-terminus with one of over 80 
different partners.
3
 The most common fusion partners, AF9, ENL, AF4, and AF10, together 
account for >90% and 50% of all MLL-driven acute lymphoblastic and myeloid leukemia, 
respectively.
4
 Leukemia driven by MLL-fusions account for approximately 10% of adult and 
60% of infant leukemia, that is associated with a poor prognosis.
5-8
 MLL-fusion interact with 
histone methyltransferase (HMT) Disrupter of Telomeric silencing 1-Like (DOT1L) directly or 
indirectly in macromolecular complexes that promote transcriptional elongation, including ENL-
associated protein (EAP, containing AF4, AF5, AF9, AF10, ENL, DOT1L, and pTEFb); AEP 
(containing AF4, AF5, ENL, and pTEFb); super elongation complex (SEC, containing AF4, 
AF9, ENL, AFF4, ELL1, and pTEFb), and DotCom (DOT1-L complex, containing DOT1L, 
AF9, ENL, AF10, AF17, and several WNT pathway modifiers).
9-13
 Despite certain variations in 
these reported multi-protein complexes, they collectively recruit the DOT1L to MLL-target 
genes, which is required for leukemogenesis. DOT1L is the only HMT known to catalyze the 
mono-, di- and trimethylation of histone H3 at lysine 79 (H3K79) that shows a high correlation 
with active gene transcription.
14
 DOT1L recruitment by MLL-fusions leads to abnormal 
methylation of H3K79 at MLL-target genes and enhanced expression of a characteristic set of 
genes that drive leukemogenesis, including HOXA9 and MEIS1.
15-17
 Inhibiting the enzymatic 
activity of DOT1L by genetic ablation or small-molecule inhibition was sufficient to suppress 
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2.2.2 DOT1L enzymatic inhibitor in clinical trials 
Pinometastat (EPZ-5676), a potent DOT1L enzymatic inhibitor, and its analogs show 
selective inhibition of DOT1L’s H3K79me activity in MLL-fusion cell lines and murine 
leukemia models, further validating DOT1L as a therapeutic target in MLL-fusion leukemia.
21-24
 
These promising results led to the initiation of phase 1 clinical trials. The first trial was a dose 
escalation trial to monitor for toxicity, optimal dose and efficacy in adult patients with 
relapsed/refractory leukemia. Out of 49 patients, only 6 had an objective response determined by 
morphologic CR, cytogenic CR, PR and resolution of leukemic cutis. Even though globally 
H3K79me2 was reduced, inhibition of H3K79 dimethylation at HoxA9 and Meis1 loci varied 
from 13-91%. Despite issues with efficacy and incomplete H3K79me2 across patients, some 
patients benefited from DOT1L enzymatic inhibition.
25
 In addition to the initial trial in adults, a 
subsequent phase 1 trial in children reported ~40% of  patients having a reduction in peripheral 
and bone marrow blasts, although transient. This trial also noted adverse events in >15% of the 
patients including anemia, thrombocytopenia and leukopenia with no objective responses.
26
 
Together, both trials showed suboptimal efficacy, although some patients derived benefit when 
H3K79me2 was reduced. These studies suggest that DOT1L is a valid therapeutic target, and that 
more complete global suppression  of H3K79me may be desirable. Conversely, DOT1L’s 
enzymatic activity regulates diverse cellular functions including DNA repair and cell cycle 
regulation, cardiac function, embryogenesis, and hematopoiesis.
12,27-32
 Taking into the 
consideration that DOT1L is essential in development and that a significant percent of MLL-
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rearrangement leukemia patients are infants, it is important to develop an alternative, safer 
therapeutic strategy.  
2.2.3 Targeting the AF9-DOT1L protein-protein interaction 
In an attempt to better understand DOTL1 PPIs and gain information for small molecule 
design and targeting, our laboratory, we reported biochemical, biophysical and functional 
characterization of the PPIs between DOT1L and MLL fusions AF9/ENL.
33
 The binding site in 
DOT1L that interacts with the ANC Homology Domain (AHD) domain of AF9 and ENL was 
mapped to a 10-amino acid region (amino acids 865-874), highly conserved in DOT1L from a 
variety of species. Alanine scanning mutagenesis revealed isoleucine 867 and isoleucine 869 of 
DOT1L as essential for the interaction between AF9/ENL and DOT1L. Importantly, functional 
studies show that the mapped AF9/ENL interacting site is essential for immortalization by 
MLLAF9 and DOT1L lacking the AF9 interacting residues (Δ10) showed significant reduction 
in colony formation similar to the effects of DOT1L enzymatic inactivation.
33
 Consistent with 
our findings, a recent study reported that DOT1L has three AF9 binding sites: 638-647 (site 1) 
and 879-888 (site 3) in addition to the site 2, 865-874, identified in our study (Figure 2-1A).
34
 
Interestingly, binding motifs at site 2 and site 3 have almost identical sequence and represent the 
high-affinity motif in DOT1L. This study further confirmed that DOT1L recruitment by binding 
to AF9 is necessary for the colony-forming ability of MLL-AF9 and hematopoietic 
transformation.
34
 In addition, Kuntimaddi et al. observed that the degree of DOT1L recruitment 
to the MLL-AF9 fusion proteins differentially affects H3K79me2 and me3 levels at certain 
subsets of MLL-AF9 target genes. Recently we reported a class of peptidomimetics based on the 
7mer DOT1L peptide, providing a proof-of-concept for development of nonpeptidic compounds 
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to inhibit DOT1L activity by targeting its recruitment and the interactions between DOT1L and 
MLL-oncofusion proteins, AF9 and ENL.
35
  
2.2.4 Goals for the study 
In this study, we further investigate the importance of DOT1L recruitment by MLL-AF9 
in MLL fusion protein transformation as well as in non-leukemic hematopoiesis. Using a genetic 
approach, we compared the inhibitory effects of disrupting the AF9-DOT1L interaction and 
DOT1L enzymatic activity in leukemia cells harboring the MLL-AF9 oncoprotein as well as in 
non-leukemic adult bone marrow. We show that the interaction between AF9 and DOT1L is 
critical for MLL-AF9 driven leukemia and blocking of this PPI inhibits H3K79 methylation at 
MLL-target genes, leading to downregulated expression of MLL-target genes, cell cycle arrest, 
apoptosis, and differentiation, in a similar way as the enzymatic inhibition. Furthermore, DOT1L 
enzymatic inhibition leads to the rapid depletion of hematopoietic progenitor cells and followed 
by loss of hematopoietic stem cells (HSCs) and hematopoietic failure. Importantly, in contrast to 
DOT1L enzymatic inhibition, disrupting the AF9-DOT1L PPIs in non-leukemic cells allowed for 
sustained hematopoiesis. Overall, this study is providing evidence that targeting DOT1L 
recruitment by AF9 and leaving the enzymatic activity intact is providing therapeutic 
advantages, particularly in regards to decreased possible side effects on hematopoiesis.  
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Figure 2-1 A single amino acid change blocks AF9-DOT1L protein-protein interaction.  
(A) Protein diagram of DOT1L highlighting the catalytic domain mutation from residues 163-
165 and AF9 binding domains at residues 638-647, 865-874 and 879-888. The red boxes indicate 
regions of the protein that were mutated for the following studies. (B) Fluorescence Polarization 
assay showing the that the 10mer peptide from residues 865-874 can compete for binding with 
AF9 with a fluorescein-labeled DOT1L peptide with a KI of 20nM; whereas, mutating Isoleucine 
867 to alanine can no longer bind AF9 with a KI greater than 2µM.  (C) Schematic of the process 
of generating f/f DOT1L MLL-AF9 cell lines with different DOT1L constructs reintroduced. 
Cells were harvested from the bone marrow of f/f DOT1L CreERT2 mice. The bone marrow was 
lineage depleted and transduced will MLL-AF9. MLL-AF9 were selected by neomycin treatment 
then subjected to a secondary transduction with either MigR1 as an empty vector control of one 
of four DOT1L constructs including, DOT1l-WT, DOT1L-Δ10, DOT1L-I867A (Δ10 and I867A 
mutants block AF9-DOT1L interaction), and DOT1L-RCR (enzymatically inactive DOT1L 
protein). These cells were then GFP sorted and used for DOT1L excision studies. (D) co-
Immunoprecipitation (co-IP) using Flag-MLL-AF9 to pulldown HA-DOT1L in the five 
established murine cell lines showing disruption of the MLL-AF9 and DOT1L protein-protein 
interaction in the Δ10 and I867A mutants cell lines as well as the MigR1 cell line where HA-
DOT1L is not present with corresponding Rb (rabbit) and Ms (mouse) IgG controls.  
 
2.3 Results 
2.3.1 Characterization of MLL-AF9-transformed cells in the presence of different 
DOT1L constructs  
Our previous work identified a direct interaction between the AHD of AF9 and ENL with 
the DOT1L 10 amino acid region, aa 865-874 (Figure 2-1A), deeming residues, L865, I867, 
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I869, and L871, as critical for their binding.
33
 Using a fluorescence polarization (FP)-based 
assay, we confirmed that the DOT1L WT 10-mer peptide binds AF9 with a KI of 20 nM, 
whereas, the mutant I867A 10-mer peptide does not show binding up to 10 M (Figure 2-1B), 
demonstrating that the I867A point mutation is sufficient to disrupt the AF9-DOT1L interaction. 
An independent study confirmed the 10 amino-acid interaction site and identified two additional 
DOT1L motifs as AF9 binding sites: aa 638-647 and aa 879-888 (Figure 2-1A).
34
  
Based on these studies and to further validate the consequences from blocking the AF9-
DOT1L PPI in leukemic cells, we established several MLL-AF9-transformed cell lines. Bone 
marrow from floxed Dot1l mice,
30
 were transduced with a leukemogenic MSCV-MLL-AF9 
construct. Several Dot1lf/f CreER(T2)
+
, MLL-AF9, cell lines were established carrying retroviral 
vectors expressing either HA-tagged wild type DOT1L (WT-DOT1L), DOT1L lacking 10 amino 
acid AF9 binding site, aa865-874 (Δ10-DOT1L), DOT1L mutated at I867 to alanine, which 
completely abrogates binding of DOT1L to AF9  (I867A-DOT1L), DOT1L with a GSG to RCR 
mutation in the SAM-binding domain lacking enzymatic activity (RCR-DOT1L), or MigR1 
empty vector control (Figure 2-1C).
18,36,37
 The expression of exogenous MLL-AF9 and that of all 
DOT1L constructs was validated by qRT-PCR, showing that all cell lines generated contained 
transcripts for both MLL-AF9 and DOT1L except the empty vector cell line expressing only 
MLL-AF9 (Figure 2-2A). This expression profile was confirmed by western blot detection of 
HA-tagged DOT1L and Flag-MLL-AF9 proteins as expected (Figure 2-2B).  
To validate that our Δ10-DOT1L and I867A-DOT1L cell lines have blocked DOT1L 
recruitment in comparison to our negative control MigR1 cell line and our PPI intact cell lines 
WT-DOT1L and RCR-DOT1L, we used co-immunoprecipitation (co-IP). As expected, MLL-
AF9 was unable to immunoprecipitate the Δ10 DOT1L and I867A DOT1L proteins, whereas 
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WT DOT1L and RCR DOT1L proteins with intact AF9-DOT1L interaction site had preserved 
interactions (Figure 2-1D). To further verify the interactions between AF9 and DOT1L in cells, a 
Duolink Proximity Ligation Assay (PLA) was used. Oligonucleotide PLA probes coupled to 
secondary antibodies that recognize the primary antibodies used to detect the HA (DOT1L 
constructs) and Flag (MLL-AF9) tagged proteins producing a red signal that can be detected 
using fluorescent microscopy. As expected, we detected the interaction between MLL-AF9 with 
WT DOT1L and RCR DOT1L since both of these DOT1L constructs retain the capability to 
interact with AF9. In contrast, the PLA signal was not observed in the Δ10-DOT1L and I867A-
DOT1L mutant cell lines where DOT1L recruitment was inhibited (Figure 2-2C). Overall, these 
results demonstrate that established MLL-AF9 transformed cell lines with different exogenous 
DOT1L constructs can be used to study and compare the biological effects inhibiting DOT1L 





Figure 2-2 Validation of the expression and interaction of DOT1L constructs and MLL-
AF9 in established murine cell lines.  
 (A) Expression levels of HA-DOT1L constructs and MLL-AF9 in the established cell lines. 
Cells containing mutant constructs have a higher level of transcript present than WT; however, 
the expression of wild type is sufficient for rescuing the phenotype of endogenous DOT1L 
deletion. However, no significant difference in MLL-AF9 expression and corresponding 
GAPDH control (B) Western Blot of lysate from MLL-AF9 cell lines with different DOT1L 
constructs showing that the HA-DOT1L and Flag-MLL-AF9 constructs are expressed and 
recognized by the HA and Flag antibodies that were using in subsequent experiments in the 
MLL-AF9 cell lines (C) Proximity Ligation Assay (PLA) of the Flag tagged MLL-AF9 murine 
cell lines with MigR1-HA-DOT1L constructs and average  quantification of PLA signal per cell. 
The cells were fixed with EtOH and incubated with HA and Flag antibodies to capture the AF9-
DOT1L interaction. The first column shows the DAPI staining showing the presence of cells 
followed by the GFP that is showing the cells that is expressing the DOT1L constructs and the 
last column show the PLA signal that is observed when the two antibodies are in close proximity 
indicating a protein-protein interaction. (Olympus IX83 Inverted Microscope; Original 
magnification x200) 
2.3.2 Targeted disruption of protein-protein interactions between MLL-AF9 and DOT1L 
suppress leukemia cell growth and promotes their differentiation and apoptosis 
To examine the importance of DOT1L recruitment by MLL-AF9 in leukemic cell 
proliferation, the above characterized Dot1lf/f CreER-T2
+
 MLL-AF9 cell lines were cultured in 
the presence of 4-OHT or the EtOH vehicle. These studies allowed us to evaluate and compare 
the effect of blocking the AF9-DOT1L PPI with the hallmark phenotypic response from DOT1L 
enzymatic inhibition. Dot1l excision was maintained as shown by genotyping the cell lines at the 
termination of the experiment (Figure 2-3A).  
Figure 2-3 Dot1L excision is maintained throughout the course of the experiment.  
(A) Genotyping of f/f DOT1L CreERT2 MLL-AF9 cell lines with DOT1L constructs showed 
excision of endogenous DOT1L for the duration of the experiment. The figure shows a 
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representative genotyping at Day 3. Genotyping primers GAAGTTCCTATTCCGAAGTT and 




Figure 2-4: Assessing 7.5nM 4-OHT is toxicity and Cre induction in the DOT1L constructs 
and MLL-AF9 in established murine cell lines.  
(A) WT DOT1L CreERT2 MLL-AF9 cells were treated with 7.5nM tamoxifen (4-OHT) 
showing no effect on cell proliferation (B) Western blot showing no effect on H3K79me2 after 4 
days of 4-OHT treatment. 





 murine cells were treated with 4-OHT, demonstrating no effect on cell 
proliferation or H3K79me2 methylation status of the cells (Figure 2-4A-B). As expected, upon 
treatment with 4-OHT, the MigR1 and enzymatically deficient RCR-DOT1L cell lines did not 
sustain cellular proliferation.
15,16,33,34
 Control leukemia cells expressing WT-DOT1L showed a 
rescue of proliferation, confirming that the observed phenotype was due to loss of Dot1l and its 
HMT activity. Strikingly, the Δ10-DOT1L and I867A-DOT1L cell lines exhibited high 
sensitivity to blocking of the AF9 and DOT1L PPI showing a significant decrease in cell 
proliferation to the same extent as MigR1 and RCR-DOT1L cells (Figure 2-5A).  These findings 
provide strong evidence that disrupting the interactions between MLL-AF9 and DOT1L by the 
previously identified minimum targeting domain (Δ10; 865-874 aa), and by a single point 
mutation (I867A) effectively inhibits MLL-AF9 cells proliferation.  
To dissect the underlying mechanisms for the induced anti-leukemic effect and confirm 
the disruption of DOT1L recruitment to the MLL target gene loci, HOXA9 and MEIS1, a 
45 
 
chromatin immunoprecipitation coupled with qPCR (ChIP-qPCR) was performed (Figure 2-5B). 
As expected, WT-DOT1L and RCR-DOT1L with an intact AF9-binding domain, were 
immunoprecipitated at the promoter region of both loci. Moreover, in Δ10-DOT1L and I867A-
DOT1L leukemia cells, DOT1L localization to these loci was significantly reduced (Figure 2-
5C). To confirm that loss of DOT1L recruitment was solely due to blocked recruitment by MLL-
AF9, we also performed ChIP for Flag-MLL-AF9, showing its equal localization across the cell 
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Figure 2-5 MLL-AF9 mediated proliferation is dependent on the interaction and 
recruitment of DOT1L.  
(A) Cells were treated at day 0 and day 2 with 7.5nM tamoxifen (4-OHT) and monitored for cell 
proliferation. Mutating the AF9-DOT1L interaction site (Δ10 and I867A) significantly reduces 
cellular proliferation at a similar level to complete deletion (MigR1) or enzymatic inhibition 
(RCR) of DOT1L in MLL-AF9 cells. (n≥4) (B) Schematic representation of HoxA9 and Meis1 
gene loci with arrows indicating the location of chromatin Immunoprecipitation qPCR (ChIP-
qPCR) primers for the promoter region. (C) Using an anti-HA antibody, DOT1L constructs were 
immunoprecipitated, showing disruption of the MLL-AF9 and DOT1L interaction at the HoxA9 
and Meis1 promoter. Only WT and RCR constructs with the intact PPI interaction site were 
detected. There was minimal to no enrichment over background for I867A and Δ10. (D) An anti-
Flag ChIP-qPCR for MLL-AF9 showed no significant difference in localization to both HoxA9 
and Meis1 promoters in each cell line with corresponding % input control (representative data 
from 2 independent experiments). Significance key calculated using a t-test on Prizm 6 software 
(ns P> 0.05, * P≤ 0.05, ** P≤ 0.01, *** P≤ 0.001, **** P≤ 0.0001). 
 
Figure 2-6 ChIP at Intron 8 of Meis1.  
(A) ChIP-qPCR using an HA antibody, DOT1L constructs were pulled down showing discretion 
of the MLL-AF9 and DOT1L interaction at Intron 8 of Meis1. Only WT and RCR constructs 
with the intact PPI interaction site were detected. There was minimal to no enrichment over 
background for I867A and Δ10. A Flag ChIP-qPCR for MLL-AF9 showed no significant 
difference in localization to both HoxA9 and Meis1 promoters in each cell line. (B) With an 
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antibody for H3K79me2, we confirmed the decrease in methylation at the Meis1 gene locus t 
intron 8 in the MigR1, Δ 10, I867A and RCR cells in comparison to WT with corresponding % 
input control. (representative data from 2 independent experiments) 
 
Previously, we observed that cells containing WT-DOT1L and Δ10-DOT1L with intact 
HMT domain were able to retain H3K79me2 after the first round of plating in colony-formation 
assay, while RCR-DOT1L failed to restore H3K79me2.
33
 However, after the second round of 
plating there were not enough Δ10-DOT1L cells remaining to measure H3K79me, so no 
endpoint H3K79me was taken. In this study, we overcame that limitation and observed an 
overall slower change in global H3K79me2 in the PPIs mutant cells in comparison to cells 
expressing RCR-DOT1L. On day 2, Δ10-DOT1L and I867A-DOT1L showed modest changes in 
H3K79me2, while RCR mutation leads to a global loss of H3K79me2. By day 3, all engineered 
cell lines showed no detectable H3K79me2 (Figure 2-7A-B). Thus, different kinetic rate of 
histone methylation changes was observed on the global H3K79me2 level comparing constructs 
with impaired AF9 binding site, Δ10-DOT1L and I867A-DOT1L which showed modest 
decrease in this epigenetic mark, versus RCR-DOT1L cells with complete loss of H3K79me2 at 
day 2. To further assess the effects disrupting the DOT1L and AF9 interactions in MLL-AF9 
leukemia cells expressing wild type or mutant DOT1L on H3K79me when proliferation is 
slowed, we performed ChIP-qPCR for H3K79me2. As expected, significant decreased 
H3K79me2 was identified on target genes, specifically at the Hoxa9 and Meis1 promoter region, 
as well as intron 8 of Meis1 in all cell lines (Figure 2-6B and 2-7B). These findings collectively 
provide evidence that H3K79me2 mark on the target genes, Hoxa9 and Meis1, is significantly 




 We further characterized the cause of proliferative defects in these cells and evaluated 
well-established mechanisms of cell death when DOT1L’s function is genetically or 
pharmacologically inhibited.
19,39,40
 Knowing that DOT1L primarily drives HOXA9 and MEIS1 
expression for the initiation and maintenance of MLL-AF9 leukemia, we expected that with 
H3K79me2 decreased, we would see a profound decrease in MLL-target gene expression.
41-44
 
Indeed, we saw a significant decrease in HOXA9 and MEIS1 expression in Δ10-DOT1L and 
I867A-DOT1L leukemia cells, comparable to the changes induced by MigR1 and RCR-DOT1L. 
Importantly, these results correlated well with decreased H3K79me2 and blocked recruitment of 
DOT1L at both target loci (Figure 2-7C-D) In addition to downregulation of MLL-target genes, 
several studies showed that upon DOT1L enzymatic inhibition, cells harboring the MLL-AF9 
fusion protein are driven to cell differentiation and apoptosis.
39
 Thus, we explored if our cell 
lines would recapitulate this phenotype. Δ10-DOT1L and I867A-DOT1L cells revealed that 
inhibiting DOT1L recruitment led to cell cycle arrest and apoptosis in a similar manner as 
enzymatic inactivation (Figure 2-7E). In addition, Wright-Giemsa staining confirmed alterations 
in cell morphology from leukemic myeloblasts to differentiated cells when blocking DOT1L 
recruitment. This was further validated with concurrent increased expression of the monocyte 
differentiation marker, CD14, and decreased c-Kit (CD117), a hematopoietic stem/progenitor 
marker (Figure 2-7F). Altogether, these data provide functional confirmation of the importance 
and critical role of DOT1L recruitment for MLL-AF9-driven leukemogenesis, validating the PPI 
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Figure 2-7 Disrupting the MLL-AF9 and DOT1L interaction has the same consequence on 
leukemogenesis as enzymatic inactivation of DOT1L.  
(A) H3K79me2 for Days 1-3 of the proliferation assay showing a slower decrease in protein-
protein inhibition cell lines than enzymatically inactivated or empty vector controls. (n≥2) (B) 
ChIP-qPCR for H3K79me2 for HoxA9 and Meis1 promoters plotted relative to H3 for each cell 
line, confirmed the decrease in H3K79me2 in the MigR1, Δ 10, I867A and RCR cells in 
comparison to WT. (representative data from 2 independent experiments) (C) The abundance of 
MLL target genes Meis1 and (D) HoxA9 mRNA is significantly reduced in 4-OHT-treated cells 
in comparison to EtOH-treated controls in the MigR1, Δ10, I867A, and RCR-transduced cells. 
Expression of these genes was not decreased in the WT control cell line when comparing treated 
and non-treated cells. (E) Apoptosis was measured by quantifying the percentage of cells in the 
sub G0/G1 phase of cell cycle. showing an induction of apoptosis in the MigR1, Δ10, I867A, and 
RCR cells upon 4-OHT treatment. (F) Wright-Giemsa stain of cells after 4-OHT treatment 
(Olympus IX83 Inverted Microscope; Original magnification x400) and corresponding flow 
cytometry for cell differentiation marker CD14 and progenitor marker c-Kit, showing cell 
differentiation in MigR1, Δ10, I867A, and RCR cells while WT cells retain their blast-like 
morphology and cell surface markers. (n≥2) Significance key calculated using a t-test in Prism 6  
software (ns P> 0.05, * P≤ 0.05, ** P≤ 0.01, *** P≤ 0.001, **** P≤ 0.0001). 
 
2.3.3 The role of DOT1L, its enzymatic activity and AF9-binding site in normal 
hematopoiesis 
Constitutive and conditional Dot1l knockout models show that Dot1l is essential for 
embryonic development, as well as prenatal and postnatal hematopoiesis.
30-32
 In past studies, the 
effects of Dot1l inactivation became apparent as early as 2 weeks post excision in vivo, showing 
a rapid loss of all three lineage populations as well as decreased hematopoietic stem and 
progenitor populations.
30,45,46
 However, persistent unexcised progenitors could have influenced 
the magnitude of the functional effects. Here, we aimed to identify the early events following 
highly efficient Dot1l loss in adult murine hematopoiesis. To achieve a high degree of gene 
inactivation and avoid compensation by undeleted progenitors, we introduced a type I interferon-
inducible Mx1-Cre allele to the Dot1lf/f background. The Mx1-Cre transgene encodes a Cre 
recombinase that yields robust excision of floxed genes upon poly(I:C) injection in vivo.
47,48
 
Mice were administered poly(I:C) with 3 subsequent injections and sacrificed 7 days after the 
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initial injection to inactivate Dot1l in the hematopoietic system. Bone marrow (BM) cellularity 
showed no significant differences between Dot1l-WT and Dot1l-null mice up to 1 week after 
Dot1l deletion, whereas at day 10 post-excision we started to observe a significant decrease in 
total BM cellularity (Figure 2-8A). We observed complete Dot1l excision upon poly(I:C) 
injection in Mx1-Cre+ mice (Figure 2-9A), together with decreased H3K79 methylation at days 
7 and 10 (Figure 2-8B), confirming that Dot1l was efficiently inactivated in these mice.  
We next carefully examined the impact of Dot1l excision on hematopoietic stem cell and 
progenitor populations. For long-term hematopoietic stem cells (LT-HSCs) identified by the 
CD150+CD48– Lineage–Sca-1+c-Kit+ (LSK) phenotype and for the LSK cells, there was no 
significant initial alteration in total cell numbers in the Dot1l-excised mice at day 7 (Figure 2-
9B).
49
 Downstream myeloid progenitor subsets were also evaluated by fractionating the Lineage-
c-Kit+ (LK) compartment with additional markers (CD41, CD105, CD150 and CD16/32).
50
 We 
observed a significant decrease in the number of Pre-Megakaryocyte-erythroid (Pre-
MegE:CD41-CD16/32-CD150+LK) and Granulocyte-Macrophage Progenitor (GMP:CD41-
CD16/32+LK) in Dot1l-deficient mice (Figure 2-8C-D), with a significant decrease in CFU-GM 
colony-forming activity from Dot1l-deficient bone marrow (Figure 2-8E). These findings 




Figure 2-8 DOT1L inactivation in the adult bone marrow leads to rapid depletion of 
myeloid progenitors, followed by decrease in the numbers of hematopoietic stem cells  
(A) (left) Bone marrow cellularity in Dot1lf/f Mx-Cre- and Dot1lf/f Mx-Cre+ mice 7 days post 
poly(I:C) induction (n=21/group, pooled from 5 independent experiments; mean +/- SEM). 
(right) Bone marrow cellularity decreases in Dot1lf/f Mx-Cre+ mice 10 days post poly(I:C) 
induction. (n=14-16/group, pooled from 3 independent experiments; mean +/- SEM). (B) 
Western blot shows decreased H3K79me2 in total BM at (left) day 7 and (right) day 10; (C) 
Flow cytometric analysis quantification shows Pre MegE (CD150+CD105-CD16/32-CD41-LK) 
are significantly decreased as early as (left) day 7 and continue to be depleted by (right) day 10. 
(D) Quantification of flow cytometric analysis showing granulocyte-macrophage progenitors 
(GMP) (CD16/32+CD150-CD41-LK) are significantly decreased as early as (left) day 7 and 
continue to decrease through (right) day 10. (E) Myeloid colony formation by wild-type vs 
Dot1l-null BM in CFU-GM assays (n=8/group with triplicate plates; mean +/- SEM; pooled from 
2 experiments) showing a lack of colony formation potential in Dot1l Δ/Δ mice in comparison to 
Dot1l WT. (F-H) Profound decrease in LT-HSC,  CD11b+Gr1+ BM myeloid cells, and B220+ 




Figure 2-9 Day 7 of DOT1L inactivation shows early impacts some progenitor cell 
populations.  
(A) Excision PCR showing high excision efficiency in Dot1l
f/f
 Mx-Cre+ mice (n=5/group, 





LSK), showing no alterations in Dot1l-null HSCs 7 days post deletion 
(n=20/group; pooled from 5 independent experiments; mean +/- SEM). Quantification of LK, 
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LK) Quantification shows a decrease in Pre-GM cells in mice lacking Dot1l and no 
changes in Pre CFU-E and Pro-Erythroid cells. (n=17/group; pooled from 5 independent 
experiments; mean +/- SEM). 
Figure 2-10 HSCs and progenitors are depleted 10 days after Dot1l inactivation.  




LSK), showing a 
decrease in Dot1l-null HSCs 10 days post deletion. (n=13-15/group; pooled from 3 experiments; 
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LK). Loss of Dot1l decreases Pre-GM, Pre CFU-E and Pro 
Erythroid progenitors. (n=13-15/group; pooled from 3 experiments; mean +/- SEM). 
 
Since there was no initial alteration in HSCs, but clear depletion of progenitor cells as 
early as 7 days post Dot1l excision, we evaluated hematopoiesis at a later time point. At day 10, 
Dot1l-null mice had significant depletion in LK progenitors, LSK progenitors, LT-HSCs, and 
Pre-GM cells. (Figure 2-8H and 2-10A-B). Pro-Erythroid and Pre-CFU-E cells were also 
trending downward in numbers (Figure 2-10B). Furthermore, CD11b+Gr1+ myeloid and 
B220+CD19+ B cells significantly decreased (Figure 2-8G-H). These data are consistent with a 
profound effect of Dot1l loss on a broad range of primitive HSCs and progenitor cells. 
 We next evaluated whether inhibiting the AF9-DOT1L PPI or enzymatic inhibition 
would differ in effecting hematopoiesis. WT-DOT1L, Δ10-DOT1L, I867A-DOT1L, and RCR-
DOT1L retroviral constructs were transduced ex vivo into Mx-Cre+ Dot1l f/f B6-CD45.2 mouse 
donor cells, in addition to a NUP98-HOXA10-mCherry construct. Introduction of NUP98-
HOXA10 was used to enhance the proliferation of donor HSCs ex vivo after retroviral 
transduction, based on past work showing that NUP98-HOXA10 can dramatically increase HSC 
expansion without inducing transformation.
51,52
 Indeed, cells transplanted in the absence of 
NUP98-HOXA10 allowed for frequent host-derived reconstitution after Dot1l excision, which 
prevented efficient structure-function analysis of transduced donor-derived cells (not shown). 
First, we verified that NUP98-HOXA10 could not rescue the maintenance of bone marrow HSCs 
after Dot1l excision. We used a dual color readout system where cells derived from Mx1-Cre+ 
Dot1Lf/f B6-CD45.2 and Mx1-Cre- Dot1Lf/f B6-CD45.2 were transduced with either 
Nup98HoxA10-mCherry or Nup98HoxA10-eGFP. These 4 cell populations were then mixed into 
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two complementary groups with Cre+ and Cre- hematopoietic stem cells expressing 
complementary mCherry and eGFP NUP98-HOXA10 constructs. These two groups were 
transplanted into WT B6-CD45.1 recipient mice and used for endpoint analysis after Dot1l 
excision (Figure 2-11A). LSK and myeloid cells from the Mx1-Cre+ Dot1Lf/f B6-CD45.2 mice 
did not persist in the presence of Nup98HoxA10 regardless of the mCherry or eGFP reporter 
construct (Figure 2-11B-C).  
Figure 2-11 Nup98HoxA10 does not rescue DOT1L.  
(A) Experimental schematic of Nup98HoxA10 control experiment where bone marrow from 
Mx1-Cre+ Dot1f/f or Mx1-Cre- Dot1f/f B6-CD45.2 were transduced with Nup98HoxA10-
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mCherry and Nup98HoxA10-eGFP. The cells were mixed where the Cre+ and Cre- cells had 
different Nup98HoxA10 colors to follow their growth in vivo. Cell mixtures were transplanted 
into WT B6-CD45.1 mice and 5 injections of poly(I:C) was administered 6 weeks post-
transplant. (B) (left)Representative flow panels showing the myeloid population is only 
comprised of Mx1-Cre- Dot1f/f Nup98HoxA10; whereas, Mx1-Cre+ Dot1f/f B6-CD45.2 
Nup98HoxA10 cells are not able to grow in vivo. (right) Quantification of all flow data. (C) 
(left)Representative flow panels showing the LSK population is only comprised of Mx1-Cre- 
Dot1f/f Nup98HoxA10; whereas, Mx1-Cre+ Dot1f/f B6-CD45.2 Nup98HoxA10 cells are not able 
to grow in vivo. (right) Quantification of all flow data. 
 
After ex vivo expansion, CD45.2+ hematopoietic progenitors carrying NUP98-HoxA10 
plus one of the DOT1L constructs were transplanted into irradiated B6-CD45.1 recipient mice 
allowing for a clear delineation of host and recipient-derived cells. After hematopoietic 
reconstitution, poly(I:C) was administered (Figure 2-12A). Blood from the recipient mice was 
collected 16-weeks post poly(I:C) injection and analyzed by flow cytometry for CD45.2+ donor-
derived CD11b+Gr1+ myeloid cells with both mCherry and eGFP colors (Figure 2-12B). Rates 
of transduction by the DOT1L constructs differed between the groups as shown by the various 
percentages of eGFP+mCherry+ at baseline before poly(I:C) injection. However, the presence of 
WT-DOT1L, Δ10-DOT1L, and I867A-DOT1L in donor cell populations led to an increased 
representation for eGFP+mCherry+ cells in the blood after loss of endogenous Dot1l, indicating 
that these cells were selected on the basis of exogenous DOT1L expression, and thus that these 
mutant forms of DOT1L could rescue the function of endogenous Dot1l. In contrast, empty 
vector and RCR-DOT1L did not induce a systematic increase in eGFP+ cells from 2 to 16 weeks 
post poly(I:C) injection (Figure 2-12C and Figure 2-13A). This trend was also observed in 
circulating B cells (Figure 2-12D-E and Figure 2-13B). We observed that the LT-HSC cell 
population was made up entirely of donor–derived WT-DOT1L, Δ10-DOT1L, and I867A-
DOT1L, but not RCR-DOT1L and eGFP cells (Figure 2-12F). We then tested these mice for 
persistent excision of endogenous Dot1l to account for the selection of rare escapees. As 
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observed by PCR analysis the donor cells in the eGFP and RCR-DOT1L mice retained 
endogenous Dot1l which sustained their hematopoiesis (Figure 2-12G). In contrast, short-lived 
myeloid cells harvested at the end of the experiment still had an excised endogenous Dot1l locus 
when rescued with WT-DOT1L, Δ10-DOT1L, or I867A-DOT1L. Herein, we demonstrate that 
targeting the AF9-DOT1L PPI shows no profound effects on the maintenance of non-leukemic 
hematopoiesis in adult mice and exhibits significant consequences on leukemogenesis. Thus, 
these findings validate the AF9-DOT1L PPI as a therapeutic target that overcomes the on-target 
side effects of directly targeting DOT1L activity. 
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Figure 2-12 DOT1L’s enzymatic activity is essential in hematopoiesis, but its AF9-binding 
domain is dispensable.  





donors was co-transduced ex vivo with MSCV-based constructs expressing NUP98-HOXA10-
mCherry and eGFP alone vs. eGFP + DOT1L-WT, DOT1L-D10, DOT1L I867A or DOT1L-
RCR. After ex vivo expansion, these cells were transplanted into irradiated B6-CD45.1 
recipients. After hematopoietic reconstitution, poly(I:C) was administered to inactivate 
endogenous Dot1l, followed by analysis of chimerism and Dot1l excision; (B) Representative 
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myeloid cells for mCherry and eGFP expression, before (blue) and 16 wks after (red) poly(I:C) 
(5 i.p. doses). Data from individual mice are shown. Increased representation of cells expressing 
DOT1L-WT, DOT1L-D10, and DOT1L-I867A, but not eGFP or DOT1L-RCR was seen after 







cells for mCherry and eGFP expression, before (blue) and 16 wks after (red) poly(I:C) (5 i.p. 
doses). Data from individual mice are shown. Increased representation of cells expressing 
DOT1L-WT, DOT1L-D10, and DOT1L-I867A, but not eGFP or DOT1L-RCR was seen after 
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poly(I:C); (E) LT-HSCs after poly(I:C) administration at the termination of the study. DOT1L-
WT, DOT1L-D10 and DOT1L-I867A recipients have LT-HSCs that are comprised of the donor 
cells; whereas, eGFP or DOT1L-RCR are not except for the unexcised mice; (F) PCR analysis of 






 myeloid cells 20 weeks after 
poly(I:C) administration. DOT1L-WT, DOT1L-D10 and DOT1L-I867A recipients had ongoing 
myelopoiesis with fully excised Dot1l, while eGFP and DOT1L-RCR recipients had selected 
cells escaping Dot1l inactivation. MW, molecular weight marker. 
Figure 2-13 The AF9-binding domain of DOT1L is dispensable for adult hematopoiesis.  
(A) (top) Quantification of flow data showing the donor Mx1-Cre+ Dot1f/f Nup98HoxA10 
DOT1L WT and DOT1L Δ10 cells proliferate and repopulate the myeloid cells in the host mice 
2 weeks post poly(I:C) injection. DOT1L I867A cells maintained constant due to the low starting 
cell number. Mx1-Cre+ Dot1f/f Nup98HoxA10 eGFP and DOT1L RCR cells showed no 
significant changes due to unexcised endogenous Dot1 escapee cells. (bottom) Quantification of 




 B cells did not 
have significant changes compared to baseline 2 weeks post poly(I:C) injection. (B) 
Quantification of flow data showing the donor Mx1-Cre+ Dot1f/f Nup98HoxA10 DOT1L WT, 
DOT1L Δ10, and DOT1L I867A cells proliferate and repopulate the myeloid cells in the host 
mice 4 weeks post poly(I:C) injection. Mx1-Cre+ Dot1f/f Nup98HoxA10 eGFP and DOT1L 
RCR cells showed no significant changes due to unexcised endogenous Dot1 escapee cells. 




 B cells DOT1L WT, DOT1L Δ10, and DOT1L I867A cells proliferate and repopulate the 
B cells in the host mice 4 weeks post poly(I:C) injection. (C) (left) Bone marrow (BM) 
cellularity after starting poly(I:C) administration (5 i.p. injections) at the termination of the study 
showing all mice in the various test groups had similar BM cellularity noting the eGFP and RCR 
were comprised on unexcised cells (Figure 2-12F). (right) Thymic cellularity after starting 
poly(I:C) administration (5 i.p. injections) at the termination of the study showing an increase in 
thymic cells derived from Mx1-Cre+ Dot1f/f Nup98HoxA10 DOT1L WT, DOT1L Δ10, and 




MLL-AF4, MLL-AF9, MLL-ENL, and MLL-AF10 are the most common MLL-fusions 
proteins that reside in multiprotein complexes involved in transcriptional 
activation/elongation.
53,54
 One of the mechanisms by which MLL-fusion-target genes are 
constitutively activated is by the recruitment of DOT1L.
55
 DOT1L enzymatic inhibition emerged 
as an attractive therapeutic target leading to the development of Pinometastat and other SAM 
competitive inhibitors.
40,56-58
 In the clinic, Pinometastat showed some promise with a few 
patients reaching an objective response; however, H3K79me downregulation was variable.
25,26
 
These trials further confirmed DOT1L’s HMTase activity as critical for leukemogenesis, but 
there is still concern about the potential on-target toxicities of prolonged global H3K79me 
inhibition. Pre-clinical studies have demonstrated that there is a strong functional interconnection 
between complexes formed by MLL -fusion proteins and DOT1L illustrating the central role of 
the DOT1L recruitment and H3K79 methylation in leukemogenesis.
29,55
 We and others have 
characterized the PPIs between fusion proteins AF9/ENL and DOT1L on a biochemical, 
structural and functional level as novel drug targets for MLL-fusion luekemia.
9,33,34
  
In this study, we further explore the therapeutic value of targeting DOT1L recruitment by 
MLL-AF9 in AML and elucidate the role of this PPI in non-leukemic hematopoiesis.  For this 
purpose, we established MLL-AF9 transformed leukemia cell lines transduced with several 
different DOT1L constructs, including wild type and mutants to disrupt the PPIs and enzymatic 
activity. Consistent with the essential role of DOT1L and H3K79 methylation in the initiation 
and maintenance of MLL-rearranged leukemia,
15-17
 the MLL-AF9 interaction with DOT1L play 
crucial role for MLL-AF9 transformed leukemia cells, in a similar manner to that seen with 
inhibition of the DOT1L enzymatic domain (Figure 2-5). Our work demonstrates that by 
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blocking the PPIs between MLL-AF9 and DOT1L only by a single point mutation in the AF9 
binding site of DOT1L, 1867A, we can mimic the phenotype obtained by the enzymatic 
inhibition of DOT1L leading to impaired leukemic cell growth, inducing differentiation and 
apoptosis (Figure 2-7). As expected, DOT1L mutant proteins, Δ10-DOT1L and I867A-DOT1L, 
disrupted the MLL-AF9 and DOT1L interactions, thus blocking DOT1L recruitment to the target 
Hoxa9 and Meis1 gene loci, leading to significant decrease in H3K79me2 in the promoter 
regions of these genes. Importantly, evaluation the global H3K79 methylation provided insights 
into the slower dynamic rate of the H3K79me2 loss in these cells, in comparison to the RCR-
DOT1L cells. This suggests that disruption of the AF9/ENL-DOT1L might provide a selective 
targeting of MLL fusion proteins and bring advantages and fewer adverse effects in comparison 
with the enzymatic inhibition. Overall, these data point to a potential novel therapeutic strategy 
and benefit for the treatment of patients bearing the MLL-AF9 translocation by blocking the 
recruitment of DOT1L. 
To identify and elucidate the potential therapeutic benefits of this therapeutic strategy we 
investigated the effect of DOT1L mutants with impaired AF9 binding site on non-leukemic 
hematopoiesis. There have been several reports indicating adverse effects of DOT1L loss on 
normal hematopoiesis in mice, after two or more weeks of Dot1l excision.
30,31
 In our studies, the 
focus was on assessing the early effects of Dot1l loss on hematopoiesis and identify the cell 
populations that are the most affected. We found that as early as one week after Dot1l excision, 
myeloid progenitor cells and other progenitor populations were most sensitive, while total BM 
cellularity remained normal. By day 10, BM cellularity significantly decreased with a significant 
loss of LT-HSCs cells and progenitor cells. These findings are in agreement with previous 





 The rapid effects on adult hematopoiesis upon Dot1l inactivation point towards 
the potential of on target side effects on hematopoiesis when enzymatically inhibiting DOT1L. 
Interestingly, in our studies using Δ10 and I867A DOT1L mutants, which are not recruited to 
target genes in leukemic cells, our results demonstrated a potent reconstitution of the non-
leukemic bone marrow in these mice. On the contrary, the RCR and empty vector derived cells 
revealed impaired bone marrow reconstitution with strong selection for progenitors that escaped 
excision of endogenous Dot1l. These data suggest that non-leukemic hematopoiesis can be 
sustained when the PPI between MLL-AF9 and DOT1L is disrupted, demonstrating that 
potential therapeutic advantages might be afforded by selective targeting of these PPIs.  
 We have successfully developed the first class of peptidomimetics that target PPIs 
between DOT1L and MLL-fusion partners, AF9 and ENL, based on the 10mer DOT1L 
peptide.
35
 In this series of peptidomimetics, compound 28 was the most potent in terms of 
binding affinity, with a Ki value of 9 nM against AF9 recombinant protein (Chapter 3).
35
 
Performing a coimmunoprecipitation (co-IP) experiment in HEK 293T cells co-transfected with 
Flag-DOT1L and Myc-CxxC-AF9, we demonstrated that 28 recognizes and binds to the cellular 
AF9 protein, and effectively inhibits the DOT1L−AF9 interactions in cells (Figure 2-14A). 
Together, the findings of this study provide further evidence for targeting the AF9-DOT1L 
interaction as a promising therapeutic strategy. We further propose that targeting these PPIs with 
an inhibitor like compound 28 DOT1L recruitment will be blocked leading to downregulation of 
the MLL-target genes by decreasing the H3K79 methylation, followed with induced cell 
differentiation and apoptosis. Importantly, the DOT1L enzyme activity will be left intact and will 
be able to carry out its normal functions in the hematopoietic compartment (Figure 2-14B). This 
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study provides proof-of-concept for further development of nonpeptidic, cell-permeable, 
compounds that will inhibit the AF9-DOT1L PPI in MLL-AF9 leukemia.   
 
Figure 2-14 Proposed model for targeting the AF9-DOT1L interaction with a small 
molecule. 
(A) Co-immunoprecipitation with Flag-DOT1L and Myc-CxxC-AF9 with various concentrations 
of peptidomimetic 28, that binds to the AHD domain of AF9, dose-dependently inhibits the AF9-
DOT1L interaction (ACS med. chem. Letters, 2018). (B) Based on the experimental data, 
disrupting the PPI between AF9 and DOT1L with a compound can lead to the downregulation of 
H3K79me and HoxA9 and Meis1 expression leading to cell differentiation and cell death. In 
contrast, in non-leukemic bone marrow (BM), the AF9-DOT1L interaction is dispensable 
wherein hematopoietic stem cells and progenitor cells are sustained. 
 
2.5  Materials and methods 
Fluorescence Polarization 
Competitive FP binding experiments were performed in 96-well black, round-bottom plates 
(Corning 3792) with serial dilutions of peptide or compounds, with a fixed concentration of 
MBP-AF9 (200nM) and N-Flu-DOT1L (10nM) in assay buffer (100mM NaH2PO4, 150mM 
NaCl, 0.1% β-ME, 0.01% Triton X-100). to a final volume of 125ul. The polarization units were 
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measured after mixing and incubating at room temperature for 3 hours. Negative controls with 
MBP-AF9 and N-Flu-DOT1L probe only (0% inhibition) and positive controls with N-Flu-
DOT1L probe only (100% inhibition) were included in the assay plate. IC50 values were 
determined by nonlinear regression fitting of the competitive curves using GraphPad Prism 5.0. 
Mice  
C57BL/6.Ptprca (B6-SJL, CD45.1+) were bred in-house or obtained from Charles River 
(Frederick, MD). C57BL/6 Dot1lf/f mice were obtained from Dr. Jay Hess and crossed to Mx1-
Cre+ mice for in vivo experiments, or to Cre-ERT2 mice for in vitro experiments. Specifically, 
for the C57BL/6 Dot1lf/f Mx1- Cre+ mice, breeding was complicated by genetically linked loci 
on mouse chromosome 10, although Dot1lf/+ Mx1- Cre+ progeny was eventually obtained and 
then intercrossed.
59
 Dot1l excision was achieved using poly(I:C) (Amersham; 50 μg i.p. every 2 
days for 3-5 doses) in vivo or 4-hydroxytamoxifen (4-OHT) in vitro (Sigma-Aldrich; 7.5 nM at 
experimental day 0 and day 2). Genotypes of animals were confirmed by polymerase chain 
reaction (PCR). All experiments in mice were approved by the University of Michigan’s 
Committee for the Use and Care of Animals.  
Cell line generation 
Bone marrow from Dot1lf/f CreER(T2)
+ 
mice was harvested 4 days after i.p. injection of 150 
mg/kg 5-fluorouracil (Sigma-Aldrich) and lineage-depleted using the EasySep Mouse 
Hematopoietic progenitor cell isolation kit (Stem Cell Technologies). Retroviruses were 
produced by transfecting MSCV-neo-Flag-MLL-AF9 construct into Plat E cell line with Fugene 
6 (Roche Diagnostics). Fresh viral supernatant was used for transduction of the lineage depleted 
Dot1lf/f CrER(T2)
+ 
stem cells using two subsequent rounds of spinoculation. For spinoculation, 
cells were spun at high speed in the presence of viral supernatant for 90 minutes at room 
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temperature. Cells underwent neomycin selection for 6 days and weaned off stem cell factor 
(SCF) 9 days after starting selection. These selected cells were then transduced 14 days 
following initial antibiotic selection using the same spinoculation method described above with 
one of the following vectors: MigR1 (empty vector), MigR1-HA-DOT1L (WT-DOT1L), 
MigR1-HA-DOT1L deletion aa865-874 (Δ10-DOT1L), MigR1-HA-DOT1L I867A (I867A-
DOT1L), and MigR1-HA-DOT1L RCR (RCR-DOT1L). Cells were left to recover for 3 days, 
then sorted for GFP positivity using a MoFlo Astrios FACS sorter. Cells were expanded and 
resorted to get a majority of GFP+ cells expressing the DOT1L constructs.  
Cell growth 
Cell numbers was assessed using a hemocytometer. Cells were treated with either 7.5nM 4-OHT 
or equivalent concentration of solvent (100% ethanol) on day 0 and day 2 to achieve excision 
of Dot1l, followed by daily counting. 
Chromatin Immunoprecipitation 
ChIP experiments were performed by treating the Dot1lf/f CreER-(T2) MLL-AF9 cell lines with 
the reintroduced DOT1L WT/mutant constructs or empty vector control with 7.5nM 4-OHT for 3 
days as described cell growth protocol. Briefly, 3x10
7
 cells were crosslinked with 1% 
formaldehyde, lysed with 1% SDS lysis buffer (50 mM Tris HCl pH 8, 10 mM EDTA, 1 Roche 
mini tablet of protease inhibitors diluted in 1 ml (for 10 ml), 1% SDS) and sonicated on a 
Biorupter Pico sonication device (Diabenode). Lysates were diluted in ChIP dilution buffer (1% 
triton, 1.2 mM EDTA, 167 mM NaCl, 16.7 mM Tris HCl pH8) and precleared with appropriate 
mouse or rabbit IgG beads. Cleared lysates were immunoprecipitated with anti-HA (Abcam; 
ab1424), anti-Flag (ThermoFisher), anti-H3K79me2 (Abcam; ab3594), anti-H3 (Abcam; 24834) 
using protein A/G agarose beads (SantaCruz; sc-2003). The IPs were washed with a low salt 
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(150 mM NaCl, 0.1% SDS, 20 mM Tris–HCl pH8, 2 mM EDTA, 1% Triton X-100), a high salt 
buffer (500 mM NaCl, 0.1% SDS, 1% Triton X-100, 20 mM Tris–HCl pH8, 2 mM EDTA ) and a 
stringent lithium chloride buffer (0.25 M LiCL, 1% IGEPAL CA-630, 10 Mm Tris–HCl pH8, 
1 mM EDTA, 1% sodium deoxycholate). Protein-DNA complexes were eluted in 1% SDS, 
crosslinked in high salt and treated with RNaseA and Proteinase K. DNA was purified with a 
Qiagen PCR purification kit. qPCR was performed using the SYBR-green mastermix. Primer 
sets used were: Meis1_promoter_F-
5’TCAAAGTGACAAAATGCAAGCA3’; Meis1_promoter_R-
5’CCCCCCGCTGTCAGAAG3’; Hoxa9_promoter_F-5’TGACCCCTCAGCAAGACAAAC 
3’; Hoxa9_promoter_R- 5’TCCCGCTCCCCAGACTG 3’ 
Co-Immunoprecipitation 
Cells expressing both HA-DOT1L constructs and Flag-MLL-AF9 were collected and lysed using 
BC-300 lysis buffer: 20 mM Tris-HCl pH 8.0, 300 mM KCl, 1 mM EDTA, 10% glycerol, 0.1% 
NP-40 and 1x protease inhibitor cocktail (BioMake). The lysate was pre-cleared for 2h in Mouse 
IgG Agarose (Sigma-Aldrich). The precleared lysates were incubated with different 
concentrations of the DOT1L peptidomimetic or no compound at 4°C overnight. The next day, 
the cell lysates were immunoprecipitated with anti-flag M2 magnetic beads (Sigma-Aldrich) at 
4°C for 2h. After incubation, the beads were washed extensively, boiled in SDS loading buffer 








Cells were treated with either 7.5nM 4-OHT or an equivalent concentration of solvent (100% 
ethanol) on day 0 and day 2 to achieve excision of Dot1l. On day 3, cells were washed twice 
with ice-cold PBS and resuspended in 500 μL PBS. While vortexing gently, 4.5 mL ice-cold 70% 
ethanol was slowly added followed by storage at -20°C overnight. Cell were then washed with 
PBS and incubated with 100 μg/mL RNase A and 10 μg/mL propidium iodide (Invitrogen). Cells 
were incubated for 15 minutes at 37°C and then analyzed by FACS.  
Histone Methylation 
Cells were harvested and processed using a previously reported method.
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 Histones were 
quantified using Bradford assay and normalized for SDS page electrophoresis. Anti-H3K79me2 
and anti-H3 loading controls were used for probing.  
Gene Expression 
Cells were harvested from the cell proliferation assay on day 3. RNA was isolated, and cDNA 
was synthesized using Superscript III reverse transcriptase kit (Invitrogen). Quantitative real-
time PCR was performed using SyberGreen master mix (Applied Biosystems) and primers for 
Hoxa9, Meis1, GAPDH, and beta-Actin. Data was analyzed using the 2_DD Ct method. 
Expression was normalized to GAPDH expression and was performed in triplicate. 
Differentiation 
Cells were harvested from the cell proliferation assay on day 3 and cytospun onto microscope 
slides. Cells were then stained with Wright-Giemsa stain (Millipore) and mounted on a slide with 
a coverslip using Permount (Fisher Chemical) mounting medium. Images were captured using 
bright field condition with an Olympus IX83 inverted microscope. Cells were stained with anti-
c-Kit, anti-CD14 and isotype control antibodies (BD Pharmingen, San Jose, CA & Biolegend, 
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San Diego, CA) and processed in a LSRII Flow Cytometer (BD Biosciences, San Jose, CA). 
Data was analyzed using FlowJo X.  
Flow cytometry 
Single cell suspensions were prepared from bone marrow or blood, followed by red blood cell 
lysis (ACK buffer, Cambrex, Walkersville, MD). The following antibodies were from 
BioLegend (San Diego, CA), eBiosciences (San Diego, CA) or BD Biosciences (San Jose, CA): 
anti-CD3, CD4, CD8, CD11b, CD11c, CD16/32, CD19, CD41, CD48, CD105 CD150, Gr1/Ly-
6G, B220, NK1.1, TCRβ, TCRγδ, c-Kit, and Sca-1. We used the following antibody cocktail to 
exclude Lineage+ cells: anti-CD3, CD8, CD11b, CD11c, B220, CD19, TCRβ, TCRγδ, Gr1, 
NK1.1 and Ter119. Ter119 was omitted when analyzing erythroid progenitor populations. Ki67 
staining was achieved using the BD Ki67 Set (BD Biosciences). Analysis was on FACSFortessa 
and sorting on FACSAria II/III (BD Biosciences). Dead cells were excluded with 4′6-diamidino-
2-phenylindole (Sigma) or with a fixable viability dye (Aqua Zombie, cat. 423102 BioLegend). 
Files were analyzed in FlowJo (Tree Star, San Carlos, CA). 
Retroviral transduction and bone marrow transplantation  
Donor Dot1lf/f Mx1-Cre+ CD45.2+ and Dot1lf/f Mx1-Cre- CD45.2+ mice were injected i.p. 
with 150mg/kg 5-FU to enrich for cycling HSCs. Bone marrow was harvested 4 days after 5-FU 
treatment and stimulated with SCF, IL-3 and IL-6 overnight, as described
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. To insure the viable 




B6-CD45.2 and Dot1lf/f Mx1-Cr+- CD45.2+ 
cells were co transduced ex vivo for 10 days with MSCV-based constructs expressing eGFP plus 
DOT1L-WT, DOT1L- -I867A or DOT1L-RCR and NUP98-HOXA10-mCherry so 
that we could color trace the presence of NUP98-HOXA10 in cells, in the presence or absence or 
exogenous Dot1L constructs. In selected control experiments, both NUP98-HOXA10-mCherry 
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and NUP98-HOXA10-eGFP constructs were used. On the day of transplant, 6-8-week-old B6-
SJL (CD45.1+) mice were lethally irradiated (5.5 Gy twice 4-6 hours apart, Cesium-137 source). 
Three hours after the second irradiation dose, mice were transplanted with expanded and 
retrovirally transduced progenitors. Mice were left to rest for 6 weeks before poly(I:C) injections 
started. Blood was obtained through retroorbital bleeding and transferred to EDTA-treated tubes. 
Complete blood counts were determined using the Advia 120 Hematology System (Siemens, 
Malvern, PA). Flow cytometry was performed as described above, combining eGFP and 
mCherry fluorescence with staining for selected surface markers. 
Western Blot  
Whole bone marrow was lysed with 2x Laemmli Sample Buffer (Biorad) plus 2-mercaptoethanol 
(Sigma, St. Louis, MO). For assessment of H3K79 di-methylation, lysates from 10-15 x10
5
 bone 
marrow cells were probed with Anti-H3K79me2 (Abcam, ab3594, 1:1000 dilution) and Anti-H3 
(Abcam, ab1791 1:5000 dilution). CFU-GM20,000 bone marrow cells were plated per mL of 
Methocult GF M3534 in triplicate for each biological sample (Stem Cell Technologies, 
Vancouver, BC). Colonies were counted 12 days later. 
Statistical analysis  
Comparison of two means was performed with 2-tailed unpaired Student’s t-test. Welch’s 
correction was utilized when data did not fit a normal distribution.  
2.6 Contributions 
Sierrah Marie Grigsby established the murine cell lines with contributions from James Ropa and 
Justin Serio; performed in vitro biochemical studies and cell line characterization including all 
cell proliferation, gene expression, chromatin immunoprecipitation, differentiation, and cell 
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cycle experiments. Ann Friedman; Jennifer Chase, and Bridget Waas designed conducted the in 
vivo studies. 
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CHAPTER 3 
Peptidomimetics Targeting Protein-Protein Interactions Between DOT1L and MLL 
Oncofusion Proteins AF9 and ENL 
3.1 Abstract 
MLL-AF9 and MLL-ENL have frequently identified MLL fusion proteins in human 
leukemia which mediates leukemogenesis by recruiting a methyltransferase DOT1L to the gene 
loci of MLL1 target genes, such as HOXA9 and MEIS1. The protein-protein interactions 
between DOT1L and MLL-fusion proteins, AF9 and ENL, play an essential role in the regulation 
of the H3K79 methyltransferase activity of DOT1L at the target genes; therefore, blocking these 
interactions using small molecules may represent a novel therapeutic approach for targeting this 
subset of leukemia. Based on the 7 mer peptide (peptide 2), derived from DOT1L, a class of 
peptidomimetics was designed. By modifying the side chains of the middle three residues in 
peptide 2, compound 21 was designed and achieved Ki values of 20 and 90 nM to AF9 and ENL, 
respectively, 8 times more potent than the original 7 mer peptide 2. The binding affinity of 21 
was confirmed by a biotinylated analog 22 which shows comparable affinity to both AF9 and 
ENL in two different assays, the fluorescence polarization, and the biolayer interferometry (BLI) 
binding assays. Using transiently co-transfected HEK 293t cells with Myc-tagged CxxC-AF9, it 
was demonstrated that biotinylated analog 22 recognizes and binds to the cellular Myc-CxxC-
AF9 protein in a dose-dependent manner. Modifications of the N- and C-termini of the lead 
compound 21 resulted in the identification of peptidomimetic 28 which shows 2-fold more 
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potent binding affinity to AF9 and similar binding to ENL than 21 but has much decreased 
peptidic characteristics. We also demonstrate peptidomimetic 29 is cellularly active and selective 
for MLL-AF9 transduces murine cells over a non-DOT1L dependent E2A-HLF cell line. Our 
study, for the first time, provides a foundation for the design of potent nonpeptidic compounds to 
inhibit DOT1L activity by targeting its recruitment and the interactions between DOT1L and 
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3.2 Introduction  
Translocation of the mixed lineage leukemia gene (MLL1) is one of the most common 
chromosome rearrangements found in leukemia patients.
1
 To date more than 80 genes have been 
reported to fuse with MLL1.
2
 Among MLL fusion proteins, MLL-AF4, MLL-AF9, MLL-AF10, 
and MLL-ENL account for more than 80% of MLL leukemias.
3
 AF9 and ENL are closely related 
members of YEATS domain protein family and have been identified as part of several reported 
complexes known as Super Elongation Complex (SEC), AEP (AF4, ENL, P-TEFb) and DotCom 
Complex.
4-6
 They share high homology in their C-terminal hydrophobic domain known as ANC1 
Homology Domain (AHD) that is responsible for the recruitment of several multiprotein 
complexes.
4-6
 Through these protein-protein protein interactions (PPIs) AF9 and ENL recruits 
both gene repressive complexes through CXB8 and BCoR as well as gene activating complexes 
through AF4 and DOT1L.
7-10
 Both AF4 and DOT1L share a conserved AF9/ENL binding 
domain that interacts with the same AHD domain of AF9 and ENL in a mutually exclusive 
manner.
5,11-13
 One of the molecular mechanisms of leukemogenesis is mediated by the 
recruitment of the histone methyltransferase DOT1L, Disruptor of Telomeric silencing 1-like, by 
MLL-AF9/ENL, to MLL1 target genes, such as HOXA9 and MEIS1. The recruitment of DOT1L 
results in hypermethylation of H3K79 at the HOXA9 and MEIS1 loci and sustained expression of 
these genes, which is pivotal for leukemogenesis induced by these MLL oncogenic fusion 
proteins.
14-16
 DOT1L has been validated as a therapeutic target for the treatment of MLL-
rearranged leukemias. As a result, a small molecule, SAM competitive, DOT1L inhibitor, EPZ-
5676, has entered phase I clinical trials.
17
 However, several groups, using conditional DOT1L-





, which raise the possibility of side effects by direct targeting of 
the catalytic domain. Therefore, investigating and developing alternative strategies for inhibiting 
DOT1L activity is essential and necessary.  
3.2.1 Approaches to identify inhibitors of protein-protein interactions (PPIs) 
Discovering potent inhibitors of protein-protein interactions is not as straightforward as 
targeting enzymatic function. Enzymes have a well-defined binding pocket specific to their co-
factors and substrates where a small molecule can bind with high potency and inhibit its function 
in a reversible or irreversible manner.
20
 Unlike substrate binding sites in an enzyme, PPIs do not 
have a defined binding pocket. Usually they cover a large surface of a protein with several 
essential contacts known as hot spots.
21
 The traditional method of identifying small-molecule 
inhibitors is the High Throughput screening method (HTS).
22
 Although it can be challenging, 
there are several successful examples of identifying small-molecules that target PPIs.
23-25
 
In recent years, fragment-based drug discovery (FBDD) has been widely used strategy to 
the discovery of small-molecule inhibitors that can bind in different protein’s hot spots. Usually, 
the hit fragments bind with low potency, mM to high uM, which need to be further optimized by 
applying different strategies, such as growing the identified hit fragment or linking together if 
two fragments bind to the adjacent pockets in the target protein.
26
 The successfulness of this 
strategy depends on the structural knowledge of the fragment(s) binding to the protein target. 
ABT737, an inhibitor of the PPIs between anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w and 
proapoptotic proteins, Bim, Bak, and Bax, is the first successful example for discovery and 





Another well-established strategy to discover inhibitors of PPIs is developing 
peptidomimetics.
27
 This approach has been applied to many PPIs including XIAP and caspase-9 
and developed potent Smac mimetics, currently in clinical trials, MDM2 inhibitors blocking the 
interactions between MDM2 and p53 and MLL1 inhibitors, blocking the formation of MLL1 
complex by disrupting the interactions between MLL1 and WDR5.
28-32
 These peptide-based 
small molecules are mimicking the natural peptide of the protein that interacts with the target, 
with improved drug-like properties, including solubility metabolic stability and etc.  
3.2.2 Utilizing known AF9-binding domains of DOT1L as a starting point to peptide 
design 
Our group characterized for the first time the protein-protein interactions between 
DOT1L and MLL fusion oncogenic proteins, AF9 and ENL, on a biochemical, biophysical and 
functional level.
11
 The AF9/ENL binding site in DOT1L was mapped and identified to a 10 
amino-acid region, aa 865-874 (peptide 1, Table 3-2). Peptide 1 binds to AF9/ENL and blocks 
the interaction between DOT1L and AF9/ENL in the cell lysate.
11
 Importantly, functional studies 
show that the mapped 10-amino acid interacting site is essential for immortalization by MLL-
AF9, indicating that DOT1L interaction and recruitment with MLL-AF9 are required for 
hematopoietic transformation.
11




H HSQC NMR, Kuntimaddi 
et al. confirmed the interaction site through the 10 mer peptide 1, labeled as site 2, and identified 
two additional DOT1L motifs: site 1 (aa 628-653), and site 3 (aa 878-900) which can bind to the 
same region in AF9 (aa 499-568) as site 2.
33
 The sequence between site 2 and site 3 is highly 




Table 3-1 Binding affinity of 10 mer peptides derived from binding sites 2 and 3 








We synthesized two corresponding fluorescent-labeled 10 mer peptides based on the 
sequence extracted from site 2 and site 3, respectively. Using a fluorescent polarization (FP) 
based assay, their binding affinities to AF9 and ENL were determined. Both peptides potently 
bound to AF9 and ENL, with the peptide derived from site 3 showing about 2 times more potent 
binding in comparison with the peptide derived from site 2 (Table 3-1). We and others have 
shown that DOT1L and AF4 bind with similar binding affinity and compete for the same AHD 
domain in AF9 and ENL protein.
11,33
 Consistently, NMR studies indicate that the AF4 protein,
5
 
as well as DOT1L binding motifs at sites 2 and 3, have similar binding modes to AF9.
33
 The 
NMR solution structure of the DOT1L-AF9 complex showed that DOT1L residues 879 to 884 
from site 3 form a β strand (Figure 3-1). The protein-protein interface is mainly hydrophobic, 
and the side chains of L879, V881, I883, L885, and V888 have critical hydrophobic interactions 
with AF9 (Figure 3-1). Furthermore, the amino and carbonyl groups of Val881 and Ile883 form 
two pairs of hydrogen bonds with Phe545 and Phe543 in AF9, respectively. These studies 
provide a concrete basis for using DOT1L conserved binding motif (site 2 and site 3) as a 
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promising lead structure towards the design of potent peptidomimetics and nonpeptidic 
compounds that target the interactions between MLL-AF9/ENL and DOT1L. 
 
Figure 3-1 NMR solution structure of the DOT1L-AF9 complex (PDB ID: 2MV7). 
3.2.3 Goal for Study 
 Herein, we provide the rational design for developing peptidomimetics based on the AF9 
and ENL binding site of DOT1L in order to generate chemical tools targeting this PPI. Based on 
the previously mentioned examples of PPI inhibitor design based on peptidomimetics, we aim to 
shorten and optimize DOT1L peptide binding. We first truncate the peptide to reduce the number 
of peptide bonds that are susceptible to cleavage while retaining binding to AF9 and ENL. We 
use unnatural amino acid changes to the core of the peptide to minimize protease recognition and 
improve peptide stability and to regain potency. Since the PPI is a large hydrophobic groove, 
adding hydrophobic moieties to either terminus of the peptide, we further modify the C- and N-
termini to further improve peptide, potency, stability, and cellular activity. Utilizing this strategy, 
we developed a potent and selective peptidomimetic that disrupts the AF9-DOT1L PPI, 
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downregulate MLL-target gene expression and induce cell differentiation. These data lay the 
groundwork for the further development of DOT1L peptidomimetics as future therapeutics for 
MLL-AF9/MLL-ENL leukemia. 
3.3 Results 
3.3.1 Optimization of WT DOT1L peptide  
 
Table 3-2 Optimization of the middle three residues 
 
Peptides R1 R2 R3 
AF9 IC50, μM 
(Ki, M) 
ENL IC50, μM 
(Ki, M) 






























































































In our previous study,
11
 we performed alanine-scanning mutagenesis of DOT1L peptide 1 
(Table 3-2). Four critical hydrophobic residues, L865, I867, I869, and L871, failed to tolerate 
alanine substitution with a significant decrease in binding affinity to both AF9 and ENL proteins. 
Interestingly, mutation of the last three residues in the DOT1L 10 mer peptide was well tolerated 
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and showed only a 2-6-fold decrease in the binding affinity in comparison with the wild type 
peptide.
34
 As expected, 7 mer peptide 2 showed reasonable binding affinity to AF9 with a Ki 
value of 0.16 µM, 8-fold less than 10 mer peptide 1 (Table 3-2). Importantly, the 7 mer peptide 
derived from site 3, peptide 3, showed identical binding affinity as 2 (Table 3-2), consistent with 
the binding affinities of the 10 mer peptides obtained from these two binding sites (Table 3-1). 
Therefore, in our follow up chemical modifications, we selected 7 mer peptide 2 as a promising 
lead structure for further optimization. Based on the structural information and essential key 
binding elements in DOT1L, we separated peptide 2 into three parts: the N-terminal two 
residues, the middle three residues and the C-terminal two residues (Figure 3-2). We 
demonstrated that the I867 and I869 are critical hydrophobic residues that are buried within the 
DOT1L-AF9 interface.
11
 Therefore, the peptide scaffold of the middle three residues was 
preserved to maintain the hydrogen bonds with the protein and focused on the modification of 
the I867 and I869 side chains. In the N-terminal and C-terminal dipeptide moieties, the side 
chains of L865 and L871 respectively, have hydrophobic interactions with AF9. Thus, these two 
parts were replaced with non-peptidic scaffolds and hydrophobic groups to mimic the side chains 




Figure 3-2. Modification strategy for 7 mer DOT1L peptide 2. 
 
To improve the synthetic efficiency, we used a convergent method for the synthesis of 
the designed compounds by linking different fragments. Therefore, homogeneous reactions 
instead of solid phase synthesis were used. For the convenience of synthesis, we designed 
compound 4 by replacing the primary amide in 2 with a dimethylated tertiary amide. In our FP 
competitive binding assay, 4 binds to AF9 with a Ki value of 0.30 µM and is only slightly less 
potent than 2 and 3, indicating that this modification is not detrimental to the binding. To probe 
the hydrophobic interactions of I867, we designed compounds 5-9 where the isoleucine was 
replaced with a series of natural or unnatural amino acids. The binding results showed that this 
pocket is very sensitive to the modifications, and only when the isoleucine residue is replaced 
with valine, the binding affinity can be slightly improved (5, Ki 0.17 µM). Introducing other 
amino acids at this position, such as leucine, cyclopropyl alaninel, and cyclobutyl alanine, 
resulting in reduced binding affinity by 3-5-fold (compounds 6-8). Replacing isoleucine with 
larger phenylalanine in 9, significantly decreased the binding by about 20-fold (Ki 5.62 µM), 
indicating that this pocket can accommodate a small hydrophobic group.  
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We then explored the hydrophobic interactions of I869. The NMR structure indicated that 
this pocket could accommodate a larger hydrophobic group and therefore we tried a series of 
amino acids with a larger hydrophobic side chain. Replacement of the isoleucine residue with a 
cyclopentyl glycine does not influence the binding affinity (10, Ki 0.25 µM). However, enlarging 
the five-membered ring to a six-membered ring decreases the binding affinity by two-fold (11 vs 
10). This might suggest that the pocket is not deep enough to accommodate a larger cyclohexyl 
group. Replacement of the isoleucine with leucine (12, Ki 0.83 μM) decreases the binding by 3 
fold but using an unnatural cyclopentyl alanine at this position can slightly improve the binding 
affinity. The resulted compound 13 shows a Ki of 0.13 µM in our competitive FP-based binding 
assay and is 2 times more potent than 4. Replacing the cyclopentyl ring in 13 with a cyclohexyl 
in 14 (Ki 0.18 μM) or a phenyl ring in 15 (Ki 0.28 μM) only slightly decreases the binding 
affinity. Replacing the cyclopentyl ring in 13 with a larger hydrophobic group, such as an indole 
(16) or a naphthyl group (17, 18), led to decrease binding in comparison with 13. 16 with a Ki 
0.41 μM is about three-fold less potent than 13, while β-naphthyl group containing compound 
17, is five-fold less potent (Ki 0.73 μM). The α-naphthyl ring-containing compound 18 shows a 
Ki value of 2.6 μM, being 15 times less potent than 13 and the least potent peptide in this series. 
Overall, among all the amino acids we have tried at this position, cyclopentyl alanine is the most 
optimal substitution for R3 (compound 13). 
The AF9-DOT1L NMR complex structure showed that the side chain of a serine residue, 
S882, is exposed to the solvent and has no interaction with the protein.
33
 Therefore, this residue 
was used to modify the physicochemical properties and solubility of the peptides, since the other 
residues are largely hydrophobic. Replacing serine with lysine, dramatically decreases the 
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binding affinity by 15-fold (19 vs 4), indicating that a larger group at this site is detrimental to 
the binding. Replacement of the hydroxyl group in the serine residue of 4 with an amino group 
led to the compound 20 with slightly improved Ki value of 0.19 μM. Combining the SAR 
information obtained from studying the middle three residues we designed compound 21. 
Interestingly, this compound binds to AF9 with a Ki of 0.02 μM, being 10 times more potent than 
4 and as potent as the 10 mer peptide 1. All of these compounds have been tested for their 
binding to the highly homologous ENL protein (Table 3-2). The results indicated that these 
compounds bind to ENL with 5-10 times less potent binding affinities in comparison to AF9, 
consistent with the binding profile of 10 mer DOT1L peptide 1. 
3.3.2 Further characterization of peptide 21 using biophysical and cell-based assays 
To further confirm the binding affinity of the most potent compound 21, and to determine 
whether 21 recognizes and binds cellular oncofusion proteins, a biotin-labeled analog 22 was 
synthesized. As was expected, biochemical assays show that 22 has similar low nanomolar 
binding affinities as 21 to AF9 and ENL recombinant proteins. In FP-based binding assay, 22 
shows Ki values of 10 nM and 63 nM to AF9 and ENL, respectively (Figure 3-3A). Using 
biolayer interferometry assay (BLI), it was determined that this compound binds to AF9 and 
ENL with KD values of 15 nM and 57 nM, respectively (Figure 3-3B), consistent with the Ki 
values obtained by the competitive FP-based assay. The recombinant proteins used for the 
binding studies are tagged with maltose binding protein (MBP) to preserve the stability and 
solubility of the intrinsically disordered AHD domain of AF9 and ENL proteins. The specific 
interactions of the compound 22 with fusion proteins was confirmed by testing it for its binding 
to the MBP tag protein only and didn’t show any binding (Figure 3-3C). To assess whether 
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peptide 22 can bind to the cellular AF9 oncofusion protein, we have transfected HEK 293t cells 
with Myc-tagged CxxC-AF9 protein. In streptavidin-biotin pull-down experiments, compound 
22 efficiently pulls down cellular Myc-CxxC-AF9 protein in a dose-dependent manner using 
HEK 293t cell lysates (Figure 3-3D).  
Moreover, in a competitive pull-down assay, compound 21 dose-dependently inhibits the 
binding of biotinylated compound 22 to the cellular Myc-CxxC-AF9 protein, with approximately 
60% inhibition at 100 nM (Figure 3-3E). To test if the most potent compound 21 can disrupt the 
MLL-AF9-DOT1L interaction in cells, we performed a co-immunoprecipitation (co-IP) 
experiment in HEK 293t cells co-transfected with Flag-DOT1L and Myc-CxxC-AF9 (Figure 3-
3F). In the absence of 21, DOT1L was able to pull down AF9 effectively in the cell lysate. 
Incubation of the cell lysates with various doses of 21 disrupted the DOT1L-AF9 complex in a 
dose-dependent manner. Together these experiments demonstrate that both, compounds 21 and 
biotinylated 22, recognize and bind to the cellular AF9 protein. Furthermore, 21 effectively 
competes with compound 22 providing evidence that they bind at the same AF9 binding site and 
disrupts the DOT1L-AF9 interaction and 21 effectively inhibits the DOT1L-AF9 interactions.  
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Figure 3-3 Biotinylated compound 22 
(A) Chemical structure and Ki values obtained by FP-based binding assay; (B) Binding affinity 
determined by BLI against two oncofusion proteins, AF9 and ENL; (C) Compound 22 
specifically binds to MBP-AF9 and MBP-ENL and not to MBP tag protein. (D)Pull down assay 
using HEK-239 cells transiently transfected with Myc-CxxC-AF9. (E) Compound 21 in a 
competitive manner inhibits binding of biotinylated 22 to cellular Myc-CxxC-AF9. (F) Co-IP 
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3.3.3 Modification of C-terminal and N-terminal di-peptidic motifs  
Table 3-3 Modification of the C-terminal and N-terminal dipeptidic motifs 
 







23 Me  
372± 141 
57 ± 22 
1,773 ± 194 
417± 46 
24 Et  
341 ± 75 
50 ± 15 
1,570 ± 438 
369± 103 
25 i-Pr  
369 ± 113 
57 ± 17 
1,220 ± 130 
287± 31 
26   
82 ± 17 
13 ± 3 
427 ± 74 
101± 18 
27   
149 ± 37 
23 ± 6 
237 ± 30 
56 ± 7 
28  Ph 
57 ± 17 
9 ± 3 
504 ± 39  
119± 9 
 
Towards the development of DOT1L peptidomimetics, we performed preliminary studies 
for the modifications of both the C- and N-termini (Table 3-3). In the following design, the 
middle three residues were kept as in the most potent compound 21. Both the C- and N-termini 
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dipeptide motifs contain a proline residue and a leucine residue. Among all-natural amino acids, 
proline is unique in that it can strongly influence the conformation of the peptide; therefore, in 
our initial studies, the pyrrolidine ring was kept on both termini. In peptide modifications, 
replacing the amide bond with a hetero-aromatic ring is a frequently used method to mimic the 
planar structure of the amide and to improve the metabolic stability. Thus, for the C-terminal 
modifications, we designed compounds 23-26 by replacing the amide bond between proline and 
leucine with an imidazole ring and by introducing substitute groups to mimic the side chain of 
leucine involved in interaction with AF9. In these compounds, a phenyl ring was introduced to 
the C4 position of the imidazole, and various hydrophobic groups were introduced to the N1, 
respectively. These compounds have been tested in the FP competitive binding assay, and the 
results indicated that compounds with a small hydrophobic group on N1 (23-25) had decreased 
binding affinity compared with 21. However, compound 26 which has a cyclohexyl group on N1 
shows a Ki value of 13 nM to AF9 and is slightly more potent than 21. These results suggest that 
a larger hydrophobic group at N1 could bind to a bigger hydrophobic pocket and improve the 
binding affinity.  
The acetylamido group at the N-terminus is exposed to the solvent and doesn’t interact 
with the protein. Therefore, we designed compound 27 by removing this group. Compound 27 
has a Ki value of 23 nM for AF9 protein and is about 2 times weaker than 26, indicating that the 
acetylamido group could play a role in controlling the orientation of the hydrophobic side chain 
of the leucine residue. We then designed compound 28 by replacing the 2-methyl-butyl group in 
27 with a phenyl ring. This compound binds to AF9 with a Ki value of 9 nM, about 3 times more 
potent than 27 and 2 times more potent than 21, indicating that non-peptidic modifications of the 
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two terminal residues not only can reduce the peptidic characteristic of the compounds but can 
also improve the binding affinity. 
These compounds have also been evaluated for their binding affinities to ENL. Similar to 
the 7 mer analogs, the C-terminal modified compounds 23-26 bind to ENL 5-10-fold less potent 
than to AF9. However, the N-terminal modified compounds 27 and 28 show a different trend. 27 
binds to ENL with a Ki value of 56 nM and is only 2-3 times less potent to AF9, but 28 binds to 
AF9 13-fold more potently than to ENL, suggesting that N-terminal modifications could alter the 
selectivity in binding to the two fusion proteins. As a continuation of this work, after developing 
and characterizing this small series of peptides, we aimed to develop further non-peptidic small 
molecules that bind to the AHD domain to displace DOT1L in cells. 
3.3.4 Development and characterization of cellularly active peptidomimetics 
To improve the stability and cellular permeability of the peptidomimetics, the C- and N- 
termini of 28 were further modified leading to peptidomimetic 29. 29, retained the potency of 28 
with a Ki of 10 nM to AF9 and an overall improvement of 16-fold over the initial peptide 2 
(Figure 3-4A). To test its cellular activity and to demonstrate target specific phenotype, murine 
established leukemia cell lines harboring either the MLL-AF9 fusion or E2A-HLF fusion 
proteins were used. E2A-HLF cells are known to not depend on DOT1L’s presence or function 
for leukemogenesis and act as a negative control for the initial studies since compounds which 
are disrupting the PPIs between fusion proteins and DOT1L should not show activity. As was 
expected, peptidomimetic 29 selectively killed MLL-AF9 cells in a dose-dependent manner up to 
10 M, while no effect was observed against E2A-HLF cells (Figure 3-4B-C). Importantly, this 
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translated to a dose-dependent decrease in MLL-target genes HoxA9 and Meis1 and induced cell 
differentiation (Figure 3-4D-E). 
Figure 3-4 Further chemical modifications to improve the cell permeability and stability of 
DOT1L peptidomimetics. 
(A) FP based assay showing a 10-fold improvement between peptide 21 and WT peptide 2 and a 
17-fold improvement in peptidomimetic 28 and 29 and WT 7 mer peptide 2. (B) Selectivity 
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profile of 29 showing significant killing of murine cell lines transformed with MLL-AF9 in 
comparison to E2A-HLF after 3 days of treatment. Up to 10 M there is minimal toxicity in 
E2A-HLF. (C) Cells were treated at day 0 and day 2 with peptidomimetic 29 and monitored for 
cell growth gene expression and differentiation. The compound inhibited cell growth in MLL-
AF9 murine cell line and not in E2A-HLF even at 100 nM. (D) At day 3, cells were harvested 
and tested for the gene expression of MLL-target genes HoxA9 and Meis1. (E) Wright-Giemsa 
stain of cells after treatment with 29 at various doses inducing cell differentiation at 10 𝜇M and 
300 nM (Olympus IX83 Inverted Microscope; Original magnification x400). 
 
3.4 Conclusions 
Based on the 7 mer DOT1L peptide, a series of peptidomimetics was designed and 
synthesized to improve the binding affinity to AF9 and decrease the peptidic characteristics. By 
optimizing the middle three residues, we identified peptide 21 which has a significantly 
improved binding affinity compared to the original peptide 2. Based on 21, we have performed 
preliminary modifications to both the C- and N-termini of 21. For C-terminal dipeptide motif, we 
found that the amide bond in the dipeptide can be replaced with an imidazole ring and 
hydrophobic groups can be introduced to the imidazole ring to mimic the hydrophobic 
interaction of the DOT1L leucine residue L871. For the N-terminal dipeptide motif, replacement 
of the leucine residue L865 with a suitable hydrophobic group can improve the binding affinity. 
Furthermore, modifications to the C- and N-terminal hydrophobic groups led to 
peptidomimetic 29 that has improved stability and selective cellular activity against MLL-AF9 
transformed cells that depend on DOT1L activity, but not affecting the growth of E2A-HLF cell 
line. Furthermore, 29 demonstrates on target activity by downregulating known MLL-target 
genes and inducing cell differentiation. Overall these results are providing a prove of principle 
for targeting the DOT1L recruitment and blocking its interaction with AF9 and demonstrate the 
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utility of peptidomimetics as potential chemical tools and therapeutics for MLL-rearrangement 
leukemia. 
3.5 Materials and methods 
Fluorescence Polarization (FP) binding measurements 
MBP-AF9 (487-568) was cloned into pMBP-LIC vector and MBP-ENL (489-559) into 
pMSCG9-LIC vector. Both proteins were expressed in Escherichia coli strain BL21 (DE3) 
(Invitrogen). The proteins were induced with 200 μM IPTG at 20°C and cells were harvested 
after 20 h and resuspended in cold lysis buffer (50 mM Tris HCl, pH 7.5, 150mM NaCl, 0.01% 
β-mercatoethanol). The proteins were purified by affinity chromatography employing Ni-agarose 
(Qiagen), followed by size exclusion chromatography in 50 mM Tris HCl, pH 7.5, 150 mM 
NaCl, 3 mM DTT. Purified recombinant proteins were stored at -80°C for further experiments. 
N-terminal fluorescein labeled DOT1L (N-Flu-DOT1L) 10-mer peptide (N-Flu-Ala-Ala-
LPISIPLSTV) with KD values of 45 nM and 544 nM for MBP-AF9 and MBP-ENL respectively, 
was used as a fluorescent probe in the competitive FP binding assays. The FP assays were 
carried out with serial dilutions of tested peptides and fixed concentration of N-Flu-DOT1L (10 
nM) and MBP-AF9 (200 nM) or MBP-ENL (1 µM) in assay buffer (100mM NaH2PO4, 150mM 
NaCl, 0.1% β-ME, 0.01% Triton X-100). The polarization values were measured after 3-hour 
incubation at an excitation wavelength of 485 nm and an emission wavelength of 530 nm using 
the plate reader Synergy H1 Hybrid, BioTek. IC50 values were determined by nonlinear 
regression fitting of the competitive curves using GraphPad Prism 6.0. The Ki values were 




Bio-layer interferometry (BLI) binding studies  
BLI experiments were performed using an OctetRED96 instrument from PALL/ForteBio. All 
assays were run at 30°C using HEPES buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% 
tween-20) with continuous 1000 rpm shaking. Compound 22 was immobilized on Super 
Streptavidin (SSA) biosensors by dipping sensors in 2 g/mL solution to reach saturation 
response level of 2-3 nm. Biotinylated blocked Streptavidin sensors were used as control sensors 
prepared by the protocol provided from the manufacturer. Compound 22 loaded sensors were 
dipped in a serial dilution of MBP-AF9 (aa 487-568) in concentration range from 40 to 5 nM, 
MBP-ENL (aa 489-559) from 10 to 200 nM and MBP (aa 27-392) at single concentration of 
1000 nM, and allowed to associate for 6 minutes and dissociate for 12 minutes. Buffer only 
reference was included in all assays. Collected raw kinetic data were processed in the Data 
Analysis software provided by ForteBio using double referencing for binding analysis in which 
both buffers only sensors and control sensors were subtracted. Resulting binding kinetics were 
fitted to a 1:1 binding model from which steady state KD values were calculated. 
Pull-down assay 
HEK293t cells were transfected for 48 hours with Myc-tagged CxxC-AF9 protein using Fugene 
6 (Promega). Cells were lysed in BC-300 lysis buffer (20 mM Tris-HCl, pH 8.0, 300 mM KCl, 1 
mM EDTA, 10% glycerol, 0.1% Nonidet P-40, and protease inhibitor mixture; Biomake). The 
supernatant was pre-cleared for 2h in streptavidin agarose beads (Millipore). The pre-cleared 
lysates were incubated with several concentrations of biotin-labeled 22 at 4°C overnight. For the 
competitive pull-down assay, lysate was incubated with a fixed concentration of 22 (1 M) with 
various concentrations of 21 at 4°C overnight. The next day, the cell lysate was incubated with 
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streptavidin agarose beads at 4°C for 2 hours. After extensive washing the beads with the BC-
300 lysis buffer, the pull-down samples were applied to SDS-PAGE electrophoresis and 
pulldown Myc-CxxC-AF9 protein was probed with goat monoclonal anti-Myc antibody 
(Abcam). Band quantification was analyzed using ImageJ software. 
Co-Immunoprecipitation assay 
HEK293t cells were co-transfected for 48 hours with Myc-CxxC-AF9 and Flag-DOT1L using 
Fugene6 (Promega). Cells were lysed in BC-300 lysis buffer and precleared in mouse IgG-
agarose (Sigma-Aldrich) for 2 hours. The precleared lysates were incubated with different 
concentrations of 21 at 4 °C overnight. The next day, the cell lysates were immunoprecipitated 
with anti-FLAG M2 magnetic beads (Sigma-Aldrich) at 4°C for 2 h. After incubation, the beads 
were washed extensively, boiled in SDS loading buffer, and analyzed by Western blotting using 
mouse monoclonal anti-FLAG M2 (Sigma-Aldrich) and goat monoclonal anti-Myc (Abcam) 
antibody. Band quantification was analyzed using ImageJ software. 
Cell Proliferation Assay 
Cell numbers was assessed using a hemocytometer. Cells were treated with various doses of 29 
or equivalent percentage of solvent (DMSO) on day 0 and day 2, followed by daily counting. 
Gene Expression 
Cells were harvested from the cell proliferation assay on day 3. RNA was isolated, and cDNA 
was synthesized using Superscript III reverse transcriptase kit (Invitrogen). Quantitative real-
time PCR was performed using SyberGreen master mix (Applied Biosystems) and primers for 
Hoxa9, Meis1, GAPDH, and beta-Actin. Data was analyzed using the 2_DD Ct method. 




Cells were harvested from the cell proliferation assay on day 3 and cytospun onto microscope 
slides. Cells were then stained with Wright-Giemsa stain (Millipore) and mounted on a slide with 
a coverslip using Permount (Fisher Chemical) mounting medium. Images were captured using 
bright field condition with an Olympus IX83 inverted microscope. 
3.6 Contributions 
Sierrah Marie Grigsby performed presented biochemical and biological characterization of the 
peptidomimetics synthesized by Lei Du, Aihong Yao, and Garrett Johnson.  
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Interactions of the ENL YEATS Domain Protein  
4.1 Abstract 
The human YEATS domain family proteins ENL and AF9 are homologous proteins 
containing an N-terminal YEATS domain and a C-terminal ANC1 Homology Domain (AHD). 
Both proteins recruit, DOT1L, a histone methyltransferase that activates genes, through its AHD 
domain. AF9 and ENL are commonly mutated in MLL-rearrangement leukemia, but despite 
being paralogs, MLL-AF9 and MLL-ENL leukemia in patients vary in aggression and disease 
latency. MLL-ENL is more aggressive leukemia with a 20% less 5-year survival rate than MLL-
AF9. The difference in these fusion proteins is the retention of the YEATS domain in the MLL-
ENL fusion that is lost in MLL-AF9. The YEATS domain is a highly-conserved H3K acyl reader 
motif present in a diverse family of chromatin-associated proteins. It was also reported that ENL 
YEATS domain resides in a complex with Paf1 of the PAFc complex. Based on these findings 
we hypothesized that both, recruitment of PAFc and lysine acyl reader function could potentially 
contribute to the aggressive behavior of MLL-ENL leukemia. In this chapter, the goal was to 
study MLL-ENL fusion protein and the effect of disrupting interactions with DOT1L on 
leukemic cell growth and biochemical and biophysical characterization of YEATS-ENL 
interactions. We demonstrate that established MLL-ENL cell lines containing the YEATS 
domain were significantly less sensitive to DOT1L loss than MLL-AF9. To determine if the 
YEATS domain and Paf1 interact directly or indirectly, we quantified the PPI using the 
biophysical method, BLI, and we confirmed the direct and potent interaction (KD =15 nM). 
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Furthermore, we mapped the interaction to an 80 aa region of Paf1 from 170-250 aa. Based on 
the reported studies and our exciting results, we developed a differential scanning fluorimetry 
(DSF) based binding assay for initiating a campaign for fragment-based screening and 
identifying compounds that bind to YEATS domain and either the reader function or Paf1 PPI. 
The development of these tools will allow us to further probe the YEATS interactions with Paf1 




 There are 4 classifications of acute myeloid leukemia (AML) 1) AML with recurring 
genetic aberrations 2) AML with multilineage dysplasia 3) AML, therapy-related and 4) AML 
not otherwise characterized.
1
 All of which vary in severity and disease latency. AML with 
11q23;MLL abnormalities have the poorest prognosis in comparison to intermediate, normal 
cytogenetics patients, AML with t(8;21)(a22;q22); AML1/ETO, AML with abnormal bone 
marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22); CBFB/MYH11, and acute 
promyelocytic leukemia (AML with t(15;17)(q22;q12); PML-RARA.
1
 In two independent 
studies comparing non-MLL vs MLL AML patient survival, patients with MLL aberrations have 
a 50% survival of less than 1 year in comparison to more than 2-year survival for patients with 
non-MLL genetic cytogenetics (Figure 4-1A).
1,2
 Among the various MLL-fusion leukemias, 
there is also a stratification amongst the fusions and disease progression.
1
 Clinically and in 
mouse models, out of the most common fusions, there are 3 clusters, severe, moderate and 
favorable, based on median survival.
1,3
 MLL-ENL along with MLL-AF6 and MLL-AF10 are the 
most aggressive oncofusion proteins, followed by MLL-AF9 in the moderate category, with 
MLL-AF1p as the least aggressive exhibiting a good prognosis (Figure 4-1B-C).
1,3
 AF9, ENL, 
ELL, AF10, and AF6 account for more than 70% of all MLL-rearrangement leukemia seen in 
patients.
4
 These fusions have a 63%, 45%, 60%, 44%, and 22% 5-year survival rate 
respectively.
3
 The differences in overall survival are striking among the fusions especially when 
comparing MLL-AF9 and MLL-ENL where patients have a decrease in survival by roughly 20% 




Figure 4-1 Overall survival of patients and mice with MLL1 rearrangement leukemia.  
(A) Overall survival of 1183 patients with AML according to cytogenetics.
1
 Patients harboring a 
MLL rearrangement have the poorest prognosis with 50% survival post diagnosis at less than 1 
year. (B) Survival of patients with 11q23/MLL-rearrangements of pediatric AML patients with 
various MLL-fusions.
5
 This patient data shows that amongst the various translocations there is a 
wide range of disease latencies, with MLL-AF6 being the most aggressive and MLL-AF1q as the 
least aggressive. (C) Survival curves of mice transplanted with various cell lines with differing 
MLL-rearrangements.
3
 In this mouse model, there is a clear stratification amongst the MLL-
fusions. With MLL-AF6, MLL-AF10 and MLL-ENL as the most aggressive, MLL-AF9 as 
moderate, and MLL-AF1p as least aggressive.    
 
 Interestingly, AF9 and ENL are homologous proteins containing an N-terminal YEATS 
domain and C-terminal AHD domain (Figure 4-2A-B). However, their MLL-fusion proteins 
yield a very different patient survival rate. As mentioned previously, the AHD domain has been 
well characterized in its role of recruiting both gene activating and repressive complexes 
(Chapter 1 and 2). Studies have indicated that there is a difference in the translocation point at 
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chromosomes for AF9 and ENL where MLL-AF9 has a truncated AF9 segment only containing 





Figure 4-2 YEATS domain family of protiens. 
(A)Protein schematic of the 4 human YEATS domain containing protein. (B) Phylogenetic tree 
of the YEATS proteins showing AF9 and ENL are the most similar in structure; whereas, 
GAS41 and YETS2 are more distant relatives. (C) Protein schematic of the most common MLL-
AF9 and MLL-ENL proteins found in patients.
6,7
  
4.1.1 YEATS domain as an acetylation reader 
The YEATS domain is an epigenetic reader for histone acetylation and similar 
modifications.
8,9
 This family of proteins was classified as a distinct family separate from classic 
BRD and PHD domain acetylation readers. The complex structure between AF9 YEATS domain 
with a H3K9ac peptide, showed that the protein recognized acetylated lysine by adopting an 
immunoglobulin type fold and uses a serine-lines aromatic cage to specifically read these residue 
modifications.
8
 Mutagenesis studies further showed when mutating phenylalanine 59 (F59) or 
tyrosine 78 (Y78) to alanine significantly impacted the YEATS domains ability to recognize 
acetyl-lysine and other acyl-lysine residues.
8
 The ENL YEATS domain was later crystallized 
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with an H3K27ac peptide confirming the same recognition sandwiching and dependence of the 
serine and aromatic cage with critical interactions with F59 and Y78.
10
 Functionally, the YEATS 
domain is required for AF9 and ENL recruitment to chromatin. In the absence of YEATS-H3ac 
binding, transcriptional control at H3ac enriched loci is lost.
8,11
 Moreover, targeted deletion of 
YEATS suppresses transcriptional initiation and elongate at active genes.
12
 This demonstrates 
the importance of the YEATS domain for targeting AHD associated complexes like SEC and 
DOT1L to chromatin that have been shown to be important for acute myeloid leukemia.
8,10,12
 
4.1.2 Paf1 and YEATS interaction  
 Recent studies have linked PAFc to the YEATS domain by identifying a novel 
association of PAFc subunit Paf1 to the YEATS domain. Paf1 is a part of the RNA Polymerase 
II-Association Factor complex (PAFc) along with its other subunits, CDC73, CTR9, LEO1, 
RTF1, and SKI8.
13,14
 PAFc is known for its participation in histone modification and 
transcriptional regulation ranging from initiation to termination. PAFc primarily functions 
through PPIs with histone modifiers, elongation factors, and RNA 3’-end processing factors.
15-17
 
PAFc is important in regulating many cellular processes ranging from cell cycle and 
development to tumor progression.
18
  Abnormal expression of PAFc has been correlated with 
many cancer types.
19
 Studies show the YEATS domain can target SEC and PAFc to chromatin in 
the absence of sequence-specific recruitment factors to initiate transcription elongation through 
Pol II.
20
 This study and others have implicated the YEATS domain as a potentially important 
factor for MLL-fusion leukemia.
10,12,20,21
 However, the direct interaction between the YEATS 
domain and Paf1 have not been quantified and confirmed nor has the increase in MLL-ENL 
disease severity been contributed to either the WT function of YEATS as an acetyl-lysine reader 
or the novel PAFc recruitment.  
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4.1.3 Goals for the study  
In this study, we aimed first to compare the role of DOT1L recruitment by MLL-ENL 
fusion protein in the same system described in Chapter 2 in order to compare and weigh its 
contribution to leukemogenesis in a model system. We found that while DOT1L recruitment is 
critical for MLL-AF9 leukemic cell growth (Chapter 2), in cells harboring the MLL-ENL 
rearrangement containing the YEATS domain, cell proliferation is not significantly affected. We 
next, explored the other 2-interactions that the YEATS domain could be mediating through 
MLL-ENL to drive the aberrant MLL-target gene activation. Outside of the acetylation reading 
function of YEATS, we aimed to characterize the PPI with Paf1 to determine if Paf1 directly 
interacts and recruits PAFc to MLL-target genes in addition to the already known interaction 
between the N-terminus of MLL and PAFc.
22
 In these preliminary studies, we confirmed that the 
YEATS domain interacts directly with Paf1 with a low nanomolar binding affinity of 15 nM and 
identified the interaction to the Leo1 binding site from 170-250 aa on Paf1. Furthermore, we 
developed a Differential Scanning Fluorimetry (DSF) fragment-based screening assay to identify 
molecules that could bind to the YEATS domain with the hopes to develop small molecules 
specific for inhibiting acetylation binding or Paf1 binding. The small molecules developed can 
be used as chemical tools to understand further the biology attributed to these interactions in 
leukemia and other contexts.  
4.2 Results  
4.2.1 DOT1L is not solely responsible for leukemic cell growth in MLL-ENL transformed 
cells 
Due to the similarity in the wild type AF9 and ENL proteins, they were regarded as 
having similar functions on leukemia.
23
 To address whether MLL-AF9 and MLL-ENL leukemic 
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cells have the same functional dependence on DOT1L’s enzymatic activity, Dot1lf/f CreER(T2)
+
 
cell lines carrying retroviral vectors expressing the Δ10 deletion mutant,  I867A, and a 
catalytically inactive mutant lacking H3K79 methyltransferase activity (RCR mutant) were 
generated (Figure 4-3A). These cells underwent the same treatment schedule as the MLL-AF9 
cells in Chapter 2, 7.5 nM tamoxifen every other day. We show that even when endogenous 
protein is completely removed, there is only a delay in cell proliferation; however, the cells 
continue to divide. The slowed growth is shown in both enzymatically inactivated DOT1L cells 
and the blocked recruitment cells. This data highlights that the effect on growth we are seeing is 
due to DOT1L’s recruitment which is what we see in MLL-AF9 cells; however, the effect on 
growth is significantly less in MLL-ENL than MLL-AF9 (Figure 4-3B). We also see a profound 
decrease in H3K79me2, which we know is due to the lack of DOT1L recruitment or enzymatic 
activity suggesting that targeting DOT1L alone when the YEATS domain is present in the fusion 




Figure 4-3 MLL-ENL rearaangement leukemic cells are not solely dependent on DOT1L.  
 (A) Schematic of the process of generating f/f DOT1L ENL cell lines with different DOT1L 
constructs reintroduced. Cells were harvested from the bone marrow of f/f DOT1L CreERT2 
mice. The bone marrow was lineage depleted and transduced with MLL-ENL. MLL-ENL were 
selected by neomycin treatment then subjected to a secondary transduction with either MigR1 as 
an empty vector control of one of four DOT1L constructs including, DOT1l-WT, DOT1L-Δ10, 
DOT1L-I867A (Δ10 and I867A mutants block ENL-DOT1L interaction), and DOT1L-RCR 
(enzymatically inactive DOT1L protein). These cells were then GFP sorted and used for DOT1L 
excision studies. (B) Cells were treated at day 0 and day 2 with 7.5nM tamoxifen (4-OHT) and 
monitored for cell proliferation. Mutating the ENL-DOT1L interaction site (Δ10 and I867A) 
reduces cellular proliferation at a similar level to complete deletion (MigR1) or enzymatic 
inhibition (RCR) of DOT1L in MLL-ENL cells. (n≥2) (C) H3K79me2 for Day 3 of the 
proliferation assay showing overall decrease in H3K79me2 in the PPI and enzymatic DOT1L 




Figure 4-4 Expression, purification, and characterization of recombinant Mocr-ENL 
YEATS domain.  
(A) Coomassie stained SDS page gel of the protein expression and purification steps to obtain 
pure Mocr-ENL YEATS protein used for biophysical studies. (B) Differential Scanning 
Fluorimetry (DSF) showing the obtained melting curve for the Mocr-YEATS (5-140) proteins. 
With an observed Tm between 40 and 50C. (C) DSF of recombinantly expressed Paf1 (150-531) 
with an observed Tm between 70 and 80C. (D) Association and Dissociation curves and 
constants of a H3K27ac (23-34) peptide binding to the immobilized Mocr-YEATS proteins 
giving an overall KD of 86 + 15 M.  
 
4.2.2 ENL YEATS domain directly interacts with Paf1 
 Previous studies showed a relationship between Paf1 and the N-terminal YEATS domain 
of ENL.
20,21
 However, there was a lack of quantitative characterization of the binding affinities 
between these proteins or an in-depth mapping study. Since Paf1 is associated with a generally 
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gene activating complex PAFc, we wanted to understand this interaction further. For this 
purpose, ENL YEATS protein was expressed in a Mocr-tagged vector using the purification 
method published by Li et al. (Figure 4-4A).
8
 We confirmed that the recombinant YEATS 
protein and Paf1 were well folded using differential scanning fluorimetry (DSF), obtaining a 
melting temperature of about 42C and 74C, respectively, in the tested conditions (Figure 4-4B-
C). In order to determine the binding affinity with PAF1. ENL YEATS domain was labeled with 
biotin and immobilized on biolayer interferometry (BLI) sensors. We first, confirmed the binding 
of ENL YEATS to its natural ligand, H3K27ac, and obtained a KD of 86 + 15M. Subsequently, 
different Paf1 constructs were tested for ENL YEATS binding. The smallest construct of Paf1 
(aa 170-250) showed similar binding as the full protein with KD of 15 nM demonstrating the 
YEATS-Paf1 is a direct and potent interaction (Figure 4-5).  
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Figure 4-5 Paf1 potently and directly interacts with the ENL YEATS domain.  
Representative bind curves for Paf1 170-250 aa binding to the immobilized Mocr-YEATS 
proteins giving an overall KD of 16 + 5 nM. Consistent with the binding affinities of the larger 
constructs of Paf1 proteins. 
 
4.2.3 Development of a fragment-based screen for the ENL YEATS domain 
 To further probe the importance of the YEATS domain interactions with Paf1 and 
acetylated histones in leukemogenesis, we developed a fragment-based screening method to 
identify compounds that bind to the YEATS domain. We chose to employ this strategy on the 
YEATS domain for several reasons:(1) Unlike the Paf1-YEATS interaction, the YEATS-H3ac 
interaction is weak making it difficult to develop an assay with the sensitivity to identify potent 
inhibitors of acetylated histone binding. (2) Using a fragment-based approach, we can identify 
fragments that bind various regions of the protein which gives us the flexibility of designing 
small molecules to target either interaction depending on where the fragments bind to the 
protein. (3) Moreover, we are confident in our ability to obtain structural information about the 
fragment binding surfaces due to the wealth of biophysical characterization that is already 
available (Figure 4-6A).  
The expression and purification of the ENL YEATS domain was optimized to improve 
the protein yield. We cloned the Mocr-YEATS (5-140) into a SUMO vector to increase the yield 
and simplify the purification so that we would have sufficient proteins for screening and 
crystallography. With the new SUMO tagged protein, we performed a Ni-NTA purification, 
SUMO protease cleavage, Heparin column, and anion exchange to increase the yield from 0.2 
mg, obtained from the Mocr-YEATS purification method, to 1-2 mg from a 1 L expression 
(Figure 4-6B). The heparin column was used to separate the SUMO tag and YEATS domain 
from all other contaminants (Figure 4-6C). Subsequently, the SUMO tag and YEATS solution 
113 
 
was run on an Anion-exchange to separate the tag from the YEATS protein that comes off the 
column in the flow through fraction (Figure 4-6D).  This method allows us to purify the YEATS 
domain with greater than 95% purity which is needed for screening and crystallography (Figure 
4-6E). 
 
Figure 4-6 Expression and purification of recombinant ENL YEATS domain for fragment 
based screening assay development. 
(A) Protein domain schematic and co-crystal structure (PDB: 4TMP) of ENL and H3 peptide 
noting the N-terminal interactions between the YEATS domain with Paf1 and H3 and the C-
terminal interaction between the AHD domain with AF4, DOT1L or CBX8.
21
 (B) Coomassie 
stained SDS page gel of the protein expression and purification steps to obtain pure ENL 
YEATS protein used for the fragment based screening assay. (C) HiTrap heparin column 
chromatogram showing a single, large peak containing a mixture of ENL YEATS domain and 
the cleaved SUMO tag. (D) HiTrap Q (anion exchange) column chromatogram of the ENL 
YEATS domain coming off in the flow through fractions A2-A9. (E) The pooled flow through 




After solidifying our protein preparation procedure, we tested the stability of the YEATS 
domain in various buffer conditions to identify a buffer that the protein alone would have the 
most stable Tm and in the presence of our positive control (H3K27 ac peptide) showed a dose-
dependent increase in Tm relative to the concentration tested. Out of all of the conditions 
screened, Tris, HEPES, PIPES, and sodium phosphate buffers at 25 mM with various pH and salt 
concentrations behaved the best in the assay. The 25 mM sodium phosphate pH 7.5, 250 mM 
sodium chloride buffer provided the best stabilization of the protein by itself with a Tm of 60C 
with more than half a degree increase in Tm around the measured KD from BLI (Figure 4-7A). 
We also replotted the data from the DSF experiment to generate a saturation curve plotting the 
change in Tm (Tm) over the concentration confirming the KD of the ENL YEATS domain to 
H3K27ac at ~ 80 M (Figure 4-7B). With these optimized conditions, the assay is ready for a 















25 mM Tris pH 7.0, 500 mM NaCl
25 mM HEPES pH 6.5, 250 mM NaCl, 5 mM MgCl2
25 mM PIPES pH 7.4, 250 mM NaCl
25 mM PIPES pH 7.4, 500 mM NaCl
25 mM sodium phosphate pH 7.5, 250 mM NaCl
[H3K27ac] Tm (°C) ΔTm (°C)
0 60.70 ± 0.09 0.00 ± 0.09
10 60.74 ± 0.04 0.03 ± 0.04
30 61.09 ± 0.06 0.38 ± 0.06
100 61.47 ± 0.22 0.77 ± 0.22
200 61.47 ± 0.10 0.77 ± 0.10
400 61.79 ± 0.11 1.08 ± 0.11
















ΔTm, max = 1.24 ± 0.16 °C





Figure 4-7 Development and validation of a DSF assay for high throughput fragment 
screening. 
(A) Buffer stability screen of various buffer conditions to visualize the stability of the YEATS 
domain protein noted by a change in melting temperature (Tm). More favorable buffers were 
25mM Tris, HEPES, PIPES, or sodium phosphate at pHs ranging from 6.5 to 7.4 in salt 
concentrations from 250 to 500 mM. The most stabilizing buffer was 25mM sodium phosphate 
pH 7.4 with 250 mM sodium chloride. This buffer gave a Tm of 60C and a dose-dependent 
increase in Tm in the presence of its known interactor, H3K27ac peptide. (B) The change in Tm 
(Tm) values were transformed into a saturation binging curve plotting Tm over concentration to 
H3K27ac peptide giving a KD of 80 + 30 M. 
4.3 Conclusions 
Starting from clinical observation and subsequent reports of the emerging role of the 
YEATS domain in leukemia we hypothesized that either the Paf1-YEATS or YEATS-H3 
interactions are potential mechanisms for the added aggressiveness of MLL-ENL leukemia over 
MLL-AF9. In this chapter, we focused on developing tools for further elucidating the roles of 
each interaction in leukemogenesis. For the first time, we confirm the direct, potent interaction 
between the YEATS domain and Paf1 proteins. Furthermore, we mapped the interaction to 
residues 170-250 aa of Paf1. In order to have sufficient protein for both assay optimization and 
hit validation, we optimized the expression and purification methods for the YEATS domain. 
With this pure protein, we developed a DSF-based assay to screen fragment libraries and identify 
hits that bind to the YEATS domain. Overall, the studies with the MLL-ENL leukemic cells 
highlight the need of understanding the impact of the YEATS domain on leukemogenesis, and 
with the chemical tools that we develop for both interactions, we will be able to elucidate which 






4.4 Materials and Methods 
Mice  
C57BL/6.Ptprca (B6-SJL, CD45.1+) were bred in-house or obtained from Charles River 
(Frederick, MD). C57BL/6 Dot1lf/f mice were obtained from Dr. Jay Hess and crossed to Cre-
ERT2 mice for in vitro experiments. Dot1l excision was achieved 4-hydroxytamoxifen (4-OHT) 
in vitro (Sigma-Aldrich; 7.5 nM at experimental day 0 and day 2). All experiments in mice were 
approved by the University of Michigan’s Committee for the Use and Care of Animals.  
Cell line generation 
Bone marrow from Dot1lf/f CreER(T2)
+ 
mice was harvested 4 days after i.p. injection of 150 
mg/kg 5-fluorouracil (Sigma-Aldrich) and lineage-depleted using the EasySep Mouse 
Hematopoietic progenitor cell isolation kit (Stem Cell Technologies). Retroviruses were 
produced by transfecting MSCV-neo-Flag-MLL-ENL construct into Plat E cell line with Fugene 
6 (Roche Diagnostics). Fresh viral supernatant was used for transduction of the lineage depleted 
Dot1lf/f CrER(T2)
+ 
stem cells using two subsequent rounds of spinoculation. For spinoculation, 
cells were spun at high speed in the presence of viral supernatant for 90 minutes at room 
temperature. Cells underwent neomycin selection for 6 days and weaned off stem cell factor 
(SCF) 9 days after starting selection. These selected cells were then transduced 14 days 
following initial antibiotic selection using the same spinoculation method described above with 
one of the following vectors: MigR1 (empty vector), MigR1-HA-DOT1L (WT-DOT1L), 
MigR1-HA-DOT1L deletion aa865-874 (Δ10-DOT1L), MigR1-HA-DOT1L I867A (I867A-
DOT1L), and MigR1-HA-DOT1L RCR (RCR-DOT1L). Cells were left to recover for 3 days, 
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then sorted for GFP positivity using a MoFlo Astrios FACS sorter. Cells were expanded and 
resorted to get a majority of GFP+ cells expressing the DOT1L constructs.  
Cell growth 
Cell numbers was assessed using a hemocytometer. Cells were treated with either 7.5nM 4-OHT 
or equivalent concentration of solvent (100% ethanol) on day 0 and day 2 to achieve excision 
of Dot1l, followed by daily counting. 
Protein Expression and Purification 
The ENL YEATS domain was cloned into a pMocr-LIC vector (amino acids 5-140) and a 
pHisSUMO vector (amino acids 1-148). Paf1 was cloned into a pMocr-LIC vector (amino acids 
150-200, 170-250, and 250-300) All recombinant proteins were expressed in Escherichia coli 
strain Rosetta 2 (Z-compitent cells) (Invitrogen). The proteins were induced with 400 M and 
200 M isopropyl -D-1-thiogalactopyranoside (IPTG) for ENL YEATS and Paf1; respectively, 
at 20 °C overnight. Cells with Mocr-ENL YEATS and Paf1 were lysed in pMocr lysis buffer (25 
mM Tris HCl pH 7.5, 500 mM NaCl, 2 mM BME, 10% Glycerol, 20 mM Imidazole, and 1× 
protease inhibitor). Cells with pHisSUMO-ENL YEATS were lysed in pSUMO lysis buffer (1x 
PBS, pH 7.4; Gibco, 350 mM NaCl, 10% glycerol, 10 mM Iminazole, 2 mM BME, 1 mM 
PMSF, 0.5% CHAPS. 30 μg/mL lysozyme). Lysates were purified by affinity chromatography 
employing nickel-agarose (Qiagen). SUMO-ENL YEATS was further cleaved overnight with 
SUMO protease at 4°C in dialysis buffer (1x PBS, pH 7.3, 5% glycerol, 2 mM BME). The 
cleaved mixture was further purified using a HiTrap Heparin HP column with the following 
buffers: Binding buffer (10 mM phosphate, pH 7.3 2 mM BME) and Elution buffer (10 mM 
phosphate, pH 7.3, 1 M sodium chloride, 2 mM BME). His-SUMO ENL YEATS eluted in the 
200-400 mM NaCl range. The protein underwent a buffer exchange to the Anion exchange 
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binding buffer (25 mM Tris-HCl, 100 mM NaCl, 5% glycerol, 2 mM BME, pH 7). The protein 
was further purified by a HiTrap Q HP column. The cleaved SUMO-ENL YEATS comes off of 
the column in the flow through and the SUMO tag is eluted off the column in elution buffer (25 
mM Tris-HCl, 1 M NaCl, 5% glycerol, 2 mM BME, pH 7) around 300 mM NaCl. The final pure 
protein was then analyzed by mass spectroscopy on the Q-TOF (Agilent).  
Paf1 proteins (amino acids 150-531, 150-450, 150-400, and 150-300) were provided by the 
Muntean lab.  
BLI 
Recombinant ENL YEATS domain (Mocr-ENL YEATS aa 5-140; MW = 36kDa) protein was 
biotinylated using the Thermo EZ-link Sulpho-NHS-LC-biotin biotinylation kit (cat. 21435) 
protein and biotin were mixed in a 1:1 molar ratio in PBS on ice for 2 hours. Reaction mixture 
was dialyzed in PBS buffer to remove excess biotin. 
BLI experiments were performed using an OctetRED96 instrument from PALL/ForteBio. ENL 
YEATS-Ac-peptide assays were run at 30°C using Tris buffer (25 mM Tris pH 7.4, 500 mM 
NaCl, 2 mM BME) with continuous 1000rpm shaking. Biotinylated ENL YEATS was 
immobilized on Super Streptavidin (SSA) biosensors (ForteBio) by dipping sensors in 20µg/mL 
protein solutions. Biotin labeled Streptavidin protein blocked SSA sensors were prepared were 
prepared as inactive reference controls. H3K27Ac peptide (aa 23-34; MW = 1156.3; Anaspec) 
allowed to associate and dissociate for 2 minutes.  
ENL YEATS-Paf1 assays were run at 30°C using HBS-P buffer (10 mM HEPES pH 7.4, 150 
mM NaCl, 0.005% tween-20) with continuous 1000rpm shaking. Biotinylated Mocr-ENL 
YEATS was immobilized on Super Streptavidin (SSA) biosensors (ForteBio) by dipping sensors 
in 20 µg/mL protein solutions. Biotin labeled Streptavidin protein blocked SSA sensors were 
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prepared were prepared as inactive reference controls. Recombinant Paf1 proteins were allowed 
to associate and dissociate for 1 minute 30 seconds.  
Raw kinetic data collected were processed in the Data Analysis software provide by ForteBio 
using double referencing in which both buffer only sensors and inactive protein sensors were 
subtracted. Resulting data were analyzed based on the 1:1 binding model from which kon and koff 
values were obtained and then KD values were calculated. 
DSF 
DSF was performed in a 10uL reaction mixture using 10 M of recombinant ENL YEATS 
domain (ENL YEATS aa 5-140; MW = 18kDa) protein in Tris buffer (25 mM sodium phosphate 
pH 7.5, 250 mM NaCl), various concentrations of H3K27Ac peptide (aa 23-34; MW = 1156.3; 
Anaspec) at 5% DMSO, and 2x SYPRO orange dye (ThermoFisher Scientific). Raw data was 
analyzed using Protein Thermal Shift software (Applied Biosystems) to determine Tm of the 
protein in DMSO and Protein with peptide. 
4.5 Contributions 
Sierrah Marie Grigsby developed of the MLL-ENL transduced cell lines performed cell culture 
experiments, biophysical characterization of the proteins and determined the binding affinity of 
PPIs; Sierrah Marie Grigsby and Lara Zetzsche contributed to cloning, expressing and purifying 
recombinant ENL YEATS and Paf1 proteins and optimizing the DSF screening assay.  
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Summary and Future Directions 
5.1 Summary  
Epigenetic regulators and protein-protein interactions (PPIs) are emerging as attractive 
therapeutic targets for a variety of cancers.
1,2
 This in part is due to the ineffectiveness and 
harshness of conventional cytotoxic chemotherapy agents that have been the staple of frontline 
therapy. To date, there is only 1 FDA approved drug that targets protein-protein interactions; 
Venetoclax. Venetoclax, a Bcl-2 selective inhibitor, was developed to trigger apoptosis in cancer 
cells that overexpress Bcl-2 for their survival to evade apoptosis.
3
 At this time, there are several 
PPI inhibitors in clinical trials for various indications with different targets and mechanism of 
action.
4-7
  In the context of MLL-rearrangement leukemia, DOT1L, the only H3K79 
methyltransferase, was identified and validated as a therapeutic target for several MLL driven 
leukemias including the most common MLL-AF9 and MLL-ENL.
8-10
 These fusion proteins 
recruit DOT1L to MLL target genes leading to their aberrant activation and leukemic 
transformation.
11,12
 With the initial proof-of-concept studies initiated with EPZ004777 and 
further developed clinical candidate EPZ5676, DOT1L was validated as a therapeutic target for 
MLL1 translocated leukemia.
13-15
 However, based on pre-clinical studies showing long-term 
toxicity in non-leukemic blood cell development
16,17
 and the known importance in other tissues 
like cardiomyocytes
18,19
, global enzymatic inhibition may be deleterious to patients. In this 
dissertation, we aimed to identify and validate novel therapeutic approaches to inhibit DOT1L 
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specifically in the context of MLL-fusion transformed cells while allowing the enzyme to 
function normally in its other cellular contexts. 
5.1.1 AF9 binding domain is critical for leukemogenesis and dispensable in non-leukemic 
cell growth 
Due to the importance of DOT1L in MLL-rearrangement leukemia and the emerging 
evidence of the importance of DOT1L activity in non-leukemic cell proliferation
16,17
, in chapter 
2, we designed a genetic study to validate the therapeutic advantage in targeting the PPI in 
comparison to enzymatic inactivation. We confirmed that indeed DOT1L recruitment to MLL-
target genes by MLL-AF9 is critical for leukemic transformation. More strikingly, a single 
amino acid mutation in the AF9-binding domain is sufficient to inhibit cell proliferation, 
downregulate H3H79me2 at MLL-target gene, downregulate HoxA9/Meis1 expression, induce 
cell death and cell differentiation similarly as enzymatically inhibiting DOT1L. 
We next characterized the early events of DOT1L enzymatic inactivation in non-
leukemic blood cells as a complement to previous studies that have shown hematopoietic stem 
cell depletion at later time points more than 4 weeks post inactivation.
16,17
 The study identified 
that initially, hematopoietic stem cells are not severely affected at 1-week post DOT1L 
inactivation; however, some progenitor cell populations impacted shown by a decrease in 
number and loss of self-renewal capabilities in the case for GMPs. Furthermore, as early as 10 
days after DOT1L inactivation, total bone marrow cellularity decreases with a significant 
depletion of long-term hematopoietic stem cells, indicating that the previously reported events at 
16 weeks,
16
 occur more rapidly after DOT1L is excised.  
Finally, we tested the effects of blocking DOT1L recruitment on hematopoiesis in vivo in 
comparison to enzymatic inactivation. We demonstrated that both PPI mutant cell lines were able 
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to reconstitute the bone marrow similarly to cells expressing wild type DOT1L indicating that 
the AF9-binding domain is not critical for hematopoiesis. We also noted that the mice that did 
survive in the empty vector and enzymatically inactivated groups did not have full excision of 
their endogenous DOT1L and were reconstituted with a rare population of escapee cells. These 
results together make a case for targeting the AF9-DOT1L interaction as a potential therapeutic 
approach in MLL-AF9 driven leukemia with potentially fewer side effects. 
5.1.2 The development of DOT1L peptidomimetics 
 In Chapter 3, we used the knowledge gained from our previous DOT1L interaction 
mapping studies
10
 to design inhibitors of the AF9/ENL and DOT1L interaction and reported 
NMR studies
11,20
 A class of peptidomimetics was designed based on the 7 mer peptide (peptide 
2), derived from DOT1L. The middle three residue side chains were modified from peptide 2 to 
develop compound 21 with Ki values of 20 and 90 nM to AF9 and ENL; respectively, showing a 
8-fold improvement in binding affinity. The direct binding of 21 was confirmed by its 
biotinylated counterpart 22 using BioLayer Interferometry (BLI) against both AF9 and ENL 
proteins. 22 recognizes and binds to the cellular AF9 protein in a dose-dependent manner. 
Peptide 21 was further modified on the C- and N- terminus resulting in the identification of 
peptidomimetic 28 which shows 2-fold improvement in potency binding affinity to AF9 with a 
significant reduction in its peptidic characteristics. 
 In order to improve the stability and cell permeability of the peptidomimetics, the C- and 
N- terminus were further modified. Peptidomimetic 29 showed promising selectivity profile in 
murine-derived leukemia cell lines. These peptidomimetics bind potently to the AF9 AHD 
domain with a Ki of 10 nM and displace full-length DOT1L. 29 specifically inhibits 
leukemogenesis in MLL-AF9 cells in comparison to the DOT1L independent fusion E2A-HLF, 
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decreasing HoxA9/Meis1 expression and inducing cell differentiation. These initial 
peptidomimetics are the beginning of several cellularly active analogs that we hope to further 
develop as chemical tools and eventually novel therapeutics for MLL-AF9/ENL driven leukemia 
in combination with other chemotherapy agents. 
5.1.3 ENL YEATS domain and MLL leukemia 
AF9 and ENL are homologous proteins with an N-terminal YEATS domain and C-
terminal AHD domain. Both MLL-fusion products retain the AHD domain; however, the 
YEATS domain is lost in MLL-AF9 fusion proteins. Clinical and model system studies have 
shown that MLL-ENL is more aggressive and predominantly contains both YEATS and AHD.
21-
25
  In Chapter 4, we aimed to start studies to identify the dependency of MLL-ENL leukemia on 
DOT1L recruitment and validate potential interactors with the YEATS domain to determine their 
contribution on leukemia as well. To do this, we utilized the same Dot1l f/f Cre+ mouse cells and 
transformed with MLL-ENL that contained both YEATS and AHD and DOT1L constructs. 
These studied showed a modest decrease in cell proliferation, but the cells were not as dependent 
on DOT1L as the MLL-AF9 cells that lack DOT1L’s interaction or function. This indicates that 
DOT1L contributes to leukemogenesis in these cells, but another mechanism in addition to 
DOT1L recruitment is important.  
Canonically, the YEATS domain is an acetylation reader as well as other modification 
like crotonylation.
26-29
 However, a previous study highlighted the association of Paf1 of the 
polymerase associated factor complex (PAFc) as a novel interactor with ENL YEATS 
domain.
30,31
 Since YEATS-acetyl lysine has been well characterized; we focused on mapping the 
binding site on Paf1 that interacts with ENL YEATS using direct binding assay BLI to confirm if 
the interaction was direct or through a complex. We determined an 80-residue sequence between 
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170 aa to 250 aa was sufficient to sustain low nanomolar binding between the YEATS domain 
and Paf1.  
Studies have reported the importance of YEATS chromatin binding for transcription 
initiation, and elongation of RNA polymerase II.
27
 This transcriptional regulation was reported to 
be through the YEATS domain’s ability to bind Paf1 and target PAFc and SEC to chromatin as 
well as directly recruit DOT1L to chromatin in the absence of other scaffolding machinery.
32
 
Furthermore, the YEATS domain has been identified as a transcriptional controller in acute 
leukemia.
27
 These studies are implicating the YEATS domain as a potential therapeutic target; 
however, the exact mechanism or interaction that is controlling leukemogenesis in not know. To 
understand which YEATS domain interactions are critical for leukemia, we developed a 
differential scanning fluorimetry (DSF)-based screening method to identify molecules that can 
be used to probe these interactions in normal and disease states.  
5.2 Impact and significance of the dissertation studies 
 The research presented in the dissertation reports the biological characterization of 
important protein-protein interactions between MLL-AF9/MLL-ENL and DOT1L in MLL-
fusion leukemia as well as the characterization of novel PPIs. We also show the development of 
peptidomimetics for the AF9/ENL and DOT1L interaction and the development of an assay to 
identify fragments that bind to the ENL YEATS domain towards the development of chemical 
tools. The most important scientific contributions are: 
- The use of a genetic approach in vitro in leukemic cells to clarify the importance of the 
AF9-binding domain from 865 aa to 874 aa on DOT1L for leukemogenesis. 
Demonstrating that a single point mutation in the AF9 binding site is sufficient to inhibit 
leukemic cell proliferation. Clarifying the early onset of hematopoietic defects that occur 
with global H3K79 known down in the bone marrow and the ability for targeting the 
AF9-DOT1L interaction to sustain hematopoiesis.  
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- Applying structural and mutagenesis data to aid in the establishment of Structure-Activity 
Relationship (SAR) studies to design and develop potent, cell active, and selective 
peptidomimetics to be used as chemical tools to probe AF9/ENL and DOT1L interactions 
in various cellular contexts further. 
- Illustrating the role of the YEATS domain even in the absence of DOT1L activity or 
recruitment as an important target for therapeutic intervention in combination with 
DOT1L PPI inhibition. Establishing a DSF fragment-based screening assay to identify 
fragments that can bind at various locations on the YEATS domain protein as a way to a 
build molecule that could inhibit either the acetylated histone interface or the Paf1 
binding surface.  
5.3 Future directions 
5.3.1 Characterization of the redistribution of protein-protein interactions when the AF9 
DOT1L interaction is blocked. 
As mentioned previously, there are multiple ways to target critical proteins involved in 
diseases. In this study, we validated the importance of the AF9-binding domain of DOT1L that is 
critical for leukemogenesis and dispensable in hematopoiesis. To follow up on these findings, 
studies should be done to look at the redistribution of proteins when the interaction site on 
DOT1L is blocked. These studies would ascertain the extent of the normal DOT1L interactome 
in homeostatic conditions and elucidate the changes to the DOT1L interactome associated with 
disrupting the AF9-DOT1L PPI. A label-free spectral counting approach could be used to detect 
the differential binding to the following baits: Flag-WT DOT1L, Flag-∆10aa DOT1L and Flag-
I867A DOT1L. Based on known DOT1L interactions, we expect to see AF9, ENL, AF10, β-
catenin, among several other PPIs present in the samples from the Flag-DOT1L cells. In the 
Flag-∆10aa DOT1L and I867A DOT1L cells should yield similar PPI disruptions including AF9 
and ENL; however, the degree of disruption and other changes to the DOT1L are to be 
determined from these studies. We expect to see more changes to the interactome when deleting 
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10aa in comparison to a single mutation that is specific to the AF9/ENL-DOT1L interaction. 
Another approach would be to mutate the AHD domain of AF9 and follow the redistribution of 
known AF9 binding partners CXB8 and BCoR, that are apart of known gene repressive 
complexes,
33,34
 as well as AF4 and DOT1L containing complexes
11,35
 to look at the global 
changes on their localization to gene targets. This will give us insights into how targeting the 
AHD domain effects known AF9 interaction partners, the interactome, and transcription. 
In addition to looking at the redistribution of AF9 or DOT1L in the interactome, it will be 
important to look at the global changes in gene expression when DOT1L is no longer bound to 
AF9. A previous study looked at a select few gene loci where H3K79me2/3 were altered after 
disrupting the interaction between AF9 and DOT1L
11
; however, more in-depth studies are 
needed to fully determine the potential consequences of targeting this PPI on the transcriptome. 
This could offer insights on what other pathways might be affected. These studies will help the 
field further understand the biological roles of these interactions and proactively look for long 
term implications of inhibiting this interaction and how it affects the interactome and 
transcriptome. 
5.3.3 Characterization of on target activity and selectivity of cellularly active 
peptidomimetics 
The aforementioned, studies aimed to develop peptidomimetics to uses as a framework 
for the development of molecules with the purpose of inhibiting DOT1L recruitment to MLL-
target genes by MLL-fusion proteins. With promising in vitro data showing, in a model system, 
that the peptidomimetics can inhibit full-length DOT1L recruitment and selectively kill MLL-
AF9 cells, the next steps will be to further validate their activity in established human cancer cell 
lines. Due to the genetic diversity of human cancers, it is important to see if the activity will be 
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maintained in a more complex system. Established human cell lines, like MOLM-13 (MLL-
AF9), KOPN-1 (MLL-ENL), and K562 (BCR-ABL1; negative control) will be used to determine 
the efficacy in human cell lines. The expectation is for the peptidomimetic to show efficacy in 
the MOLM-13 cell lines, potentially some efficacy, but maybe less in KOPN-1 depending on the 
isoform of the MLL-ENL fusion that it harbors, and no effect on K562. After developing a 
peptidomimetic that selectively targets in human-derived cell lines with MLL-AF9 or MLL-ENL 
translocations, expanding the studies to patient samples would be another way of demonstrating 
efficacy in human leukemia.  
We would also like to determine the pharmacokinetic (PK) and pharmacodynamic (PD) 
profiles of our most stable peptidomimetics. These studies will be instrumental in determining 
the dosing schedule and if we can achieve a suitable therapeutic range in the blood to have an 
effect. After checking these parameters, the next step would be to initiate in vivo studies to see if 
we can effectively treat systemic disease and monitor hematopoiesis. If the minimum dose 
necessary is tolerable by the animals, we would expect to clear of the leukemic cells and 
sustained non-leukemic hematopoiesis.  In the event the peptidomimetics do not pass PK and PD 
screening, then more medicinal chemistry efforts will be needed to optimize the 
pharmacochemical properties of the molecules. The further development and rigorous validation 
of these molecules will be a significant step towards the development of potent chemical tools to 
understand the biology behind these interactions and the development of a specific, tolerable 






5.3.4 Determine the function consequences of disrupting ENL YEATS domain 
interactions on leukemogenesis 
 When evaluating the dependence of MLL-ENL leukemia on DOT1L recruitment, we 
demonstrated there is not a sole functional dependence on DOT1L’s enzymatic activity. We 
hypothesize that this could be due to the retention of the YEATS domain in MLL-ENL fusion 
proteins that are lost in MLL-AF9 fusions. There are a few ways that this can be confirmed. The 
first is to utilize the same system with the Dot1l f/f Cre+ mice, transform them with MLL-ENL 
that lacks the YEATS domain and determine if we can see an ablation of leukemogenic in vitro 
when DOT1L is excised. If the cell proliferation decreases to the same degree as we see with the 
MLL-AF9 fusion protein, then we can conclude that both the YEATS domain and ENL AHD 
interactions are critical for leukemic cell growth.  
 Alternatively, based on our studies (Chapter 4) and other published work, we know that 
the YEATS domain can make two key interactions that might be influential in leukemogenesis, 
either the acyl-lysine interaction or the novel interaction with the PAFc through Paf1.
30,31,36
 To 
determine which interaction is contributing to the increase in disease severity in MLL-ENL 
leukemia, genetic studies inhibiting either acetylation binding
36
 or Paf1 interaction (Chapter 4 
and Hetzner et al.) will be implemented. These studies can be carried out in vitro as described 
previously and in vivo to elucidate the importance of these interactions and their ability to either 
sustain or inhibit leukemogenesis.  
 In addition to genetically disrupting these interactions at both ENL YEATS and/or AHD 
domains, developing chemical tools targeting either the acetylated histones or Paf1 binding to 
compliment the DOT1L peptidomimetics (Chapter 3) would allow for additional validation of 
these two targets. Utilizing the DSF screening assay described in Chapter 4, we plan to screen 
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fragment libraries in order to identify fragments that bind to the ENL YEATS domain. These 
small fragments will bind non-discriminately to the protein, and with validation and 
crystallography efforts, the various binding modes can be solved. Depending on the binding sites 
of the fragments they can be linked through medicinal chemistry efforts to make full molecules 
that can be validated for either the Paf1 interaction or acetylated histones interaction. These 
studies will be instrumental in identifying useful combinations of therapies for MLL-ENL 
leukemia.  
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